For Private Circulation OnlyVol X Issue XXXX July 2008

to do Big!

Think Big

Ipca

Ipca signs off

Mr. Bill Clinton greeting Mr. Premchand Godha at the conference

Mr. Premchand Godha addressing the press conference

Ipca signs off a Historic Deal 1 Ipca’s Anti-malarial Success 2-3

Ipca acquires Tonira 14Healing Cancer the Natural Way 16-17

InsideHighlights ...and More

International 4-5 Domestic 5-6 Human Development 7-12News 13-15 & 18-20 CSR 20-23 TQM 24-25

Medical 26-27 World Environment Day 28-29 Athal 30Silvassa & Mahad 31 Achievers’ Corner 32

Dear Ipcaites,We are glad to inform you that Ipca is the 1st company in the world with whom the Clinton Foundation has signed a partnership agreement for supply of Artesunate 50mg + Amodiaquine 153.1mg Co-blister tablets at a reduced price to the Clinton Foundation Consortium to ensure wider access. We have also signed an agreement for supply of Artemether 20mg + Lumefantrine 120mg Tablets.

Mr. Premchand Godha and Mr. Murali Sarma were invited to the Clinton Foundation office in New York for the official announcement of the partnership agreement on July 17, ‘08, which got an excellent coverage on television and in the press in the USA as well as other countries including India.

In his speech, Mr. Godha mentioned, “As one of the largest manufacturers of anti-malarial Active Pharmaceutical Ingredients and Formulations worldwide, and with over 30% of the Indian anti-malarial market, we are proud to partner with the Clinton Foundation in providing affordable and effective treatment for malaria. Ipca has been supplying anti-malarial medicines for over thirty years and treating malaria has been a personal mission of mine and my company. At Ipca, we have been spearheading our own efforts under the initiative of ‘Mission Malaria’ with the sole objective of helping treat and save millions of lives.”

Former President, Bill Clinton, announced agreements with six companies – Ipca Laboratories and Cipla (2 Formulations manufacturers), Calyx and Mangalam Drugs (2 APIs manufacturers), Holleypharm and PIDI – China (2 Artemisinin Manufacturers).

Ipca is the only company which is into production of Formulations, APIs and the crop.

Mr. Raymond Chambers, the UN Special Envoy on Malaria and Mr. Daniel Vassela, the Chairman and CEO of Novartis, were also present.

Clinton Foundation HIV/AIDS InitiativeSince 2002, the Clinton HIV/AIDS Initiative (CHAI) has assisted

countries in implementing integrated and large-scale programs

for the treatment and prevention of HIV/AIDS. CHAI provides

technical assistance, resources and also helps to reduce

prices for drugs and diagnostics, which can be accessed by

69 countries in its Procurement Consortium. Today, 1.4 million

people are benefiting from medicines purchased under the

agreements negotiated by CHAI. With the support of the Bill

and Melinda Gates Foundation, CHAI began working on malaria

in 2007 with an initial focus on supporting expanded access

to ACTs.

(L to R) Mr. Raymond Chambers, Mr. Smithesh Shah, Mr. Bill Clinton, Mr. Premchand Godha, Ms. Christine Lin,

Mr. Daniel Vasella

a Historic Deal

Mr. Bill Clinton sharing a light moment with Mr. Premchand Godha with Mr. Raymond Chambers

in the background

Mr. Bill Clinton flanked by Mr. Murali Sarma and Mr. Hasit Bhatt

The Financial Express – July 19, ‘08

Ipca labs

Ipca

Ipca

Times of India – July 19, ‘08

IpcaIpca

Business Standard – July 19, ‘08

Ipca

Ipca’s contribution to the field of anti-malarial

drugs and many other products has stregthened

its position in the international market.

We bring you the clippings of the wide media coverage that Ipca attracted with this gigantic step.

IpcaContact

Ipca’s Anti-malarial SuccessMalaria is the world’s most devastating human parasitic

infection killing a million people, affecting 500 million with 2.4 billion people at risk (40% of world population).

It has not spared Alexander the Great, Genghis Khan, Dante, Mahatma Gandhi as well as several American Presidents.

Mission Malaria

It is this very foe’s fearsome feature that inspired us to cross all barriers and join hands with those who share our vision and interests. Ipca has launched Mission Malaria committed to the cause of helping to save over a million lives lost every year.

Some facts to help understand our abilities to address this global issue:

Ipca is India’s market leader in Anti-Malarials in all dosage forms.

Over 30% market share with thrice the market share of the nearest competitor.

20% of current turnover from Anti-Malarials around US$ 50 million.

Launched a special Anti-Malarials division in India with a dedicated task force.

Ipca has garnered both experience and expertise in manufacturing and marketing Anti-Malarial formulations over for 30 years.

We are one of the World’s largest manufacturers of Artemisinin-based APIs and Formulations and also cultivate the Artemisia annua crop and extracts Artemisinin in eight states in India: Gujarat, Madhya Pradesh, Uttar Pradesh, Uttaranchal, Chhattisgarh, Rajasthan, Karnataka, Kerala.

The world’s largest manufacturer of Chloroquine Phosphate and one of the few WHO approved sources for Amodiaquine, Artesunate, Artemether and Lumefantrine.

Ipca tasted early success by introducing sugarcoated Chloroquine Phosphate tablets in 1976 which was the launching pad for the current growth and hence there is an emotional bond.

Track record of increasing production due to demand surge during epidemics.

Supply Credentials

Formulations – to UNICEF, WHO, IDA, MSF, MEG, PSFCI & Ministries of Health in Africa.

APIs – to Astrazeneca, Pfizer, Bayer, Aventis, Dafra, Mepha, Parke Davis among others.

2

Success Story

FHkeÀe Svìer-ceuesefj³ee keÀer efJepe³e - ieeLeeceuesefj³ee ³ee efJe<ecepJej efJeée keÀer meyemes efJeveeMekeÀejer efyeceejer nw, efpemekesÀ

mebke´ÀceCe mes efceefue³eve ueesie ceewle kesÀ cegBn ceW mecee peeles nw~ Fme efyeceejer ves DeueskeÌPeeb[j o ie´sì, pebiespe Keeve, oebles, cenelcee ieebOeer kesÀ meeLe meeLe DeceefjkeÀe kesÀ keÀF&

je<ì^Heefle³eeW keÀes Yeer veneR yekeÌMee~

efceMeve ceuesefj³ee

FHkeÀe ves meejer keÀefþveeF³eeB otj keÀjkesÀ, Fme SkeÀ ue#³e keÀes O³eeve cesb jKeles ngS DeHeves pewmes keÀF& DeveskeÀeW kesÀ meeLe efceuekeÀj ³en efceMeve Megª efkeÀ³ee nw~ keÀjes[eW ueesieeW keÀe peerJeve ceuesefj³ee mes veä ve nes pee³es, Fme kesÀ efue³es FHkeÀe ves efceMeve ceuesefj³ee keÀer MegªDeele keÀer nw~

nceejs efnmmes ceW pees ieefjceece³eer yeeleW nw, Gveces mes kegÀí nw,

Svìer-ceuesefj³ee kesÀ nj He´keÀej kesÀ HeÀe@c³eg&uesMeve yeveeves ceW FHkeÀe ceekexÀì ueer[j nw~

DeHeves vepeoerkeÀer keÀe@efcHeefììj keÀer leguevee ceW leerve iegvee yeæ[e ceekexÀì MesDej nesles ngS, FHkeÀe kesÀ Heeme 30… mes p³eeoe ceekexÀì MesDej nw~

Svìer-ceuesefj³ee GlHeeoeWkesÀ ®eeuet keÀejesyeej mes kegÀue efyeke´Àer 20… keÀer nw, ³eeveer ueieYeie ³etSme[er 50 v³etve (©. 2000 v³etve)

osmeer yeepeej ceW nceves Svìer-ceuesefj³ee kesÀ efueS efJeMes<e efJeYeeie Meg© efkeÀ³ee nw~

nceejs Heeme Svìer-ceuesefj³ee HeÀe@c³eg&uesMeve yeveeves Deewj yes®eves keÀe 30 mes Yeer DeefOekeÀ Je<eeX keÀe jes®ekeÀ DevegYeJe nw~

efJeée keÀe efJeMeeuelece Deeìxefceefmeefveve DeeOeeefjle SHeerDeeF Deewj HeÀe@c³eg&uesMeve Ieesue kesÀ efvecee&lee~ ³ener veneR Deeìxefceefme³ee SvetDee HeÀmeue Deewj Deeìxefceefmeefveve Deke&À yeveeves keÀe keÀece iegpejele, ceO³eHe´osMe, GÊejHe´osMe, GÊejeb®eue, íÊeermeieæ{, jepemLeeve, keÀvee&ìkeÀ Deewj kesÀjue Fve Deeþ jep³eeW ceW neslee nw~

keÌueesjeskeÌJeerve HeÀemHesÀì kesÀ efJeée kesÀ efJeMeeuelece efvecee&lee nw nce~ ³ener veneR, [yuetS®eDees ³eeveer efJeée mJeemL³e mebieþve mes ceev³elee He´eHle kegÀí SkeÀ Deceesefo³ekeÌJeerve, Deeìeamegveso, DeeìeaefceLej Deewj uegcesHewÀvì^eFve kesÀ He´ceeefCele ðeesle ceW mes SkeÀ nQ nce~

meve 1976 ceW Megiej-keÀesìs[ keÌueesjeskeÌJeerve HeÀemHesÀì ieesefue³eeW keÀer HesMekeÀMe ves FHkeÀe keÀes meHeÀuelee oer~ Jele&ceeve efJekeÀeme kesÀ efueS ³en uee@efv®ebie megiece jen yeveer efpememes SkeÀ YeeJeveelcekeÀ yebOeve keÀer jen yeveleer ®eueer ieF& nw~

J³eeHekeÀ jesieeW kesÀ oewjeve oJeeF&³eeW keÀer meyemes p³eeoe efveefce&leer keÀjves keÀe ì^@keÀ jskeÀe@[& nw~

meHuee³e ¬esÀ[eqvMe³eume

nce [yuetS®eDees, DeeF[erS, SceSmeSHeÀ, SceF&peer, ³etefvemesHeÀ (Ieevee, meerje efue³eesves, keÀeWiees He´peeleebef$ekeÀ ieCejep³e, meesceeefue³ee, efueyesefj³ee SJeb yeªC[er)~ mJeemL³e ceb$eeue³e (yejkeÀervee HeÀemees, kesÀceªve, ces[eieemkeÀj, yesefveve, mesveerieue, met[eve, ceewpeeefcyekeÀ Deewj ceeueer) keÀes HeÀe@c³et&uesMeve Ieesue keÀer DeeHetefle& keÀjles nQ~ nceejs Heeme He´efle Je<e& 3 efyeefue³eve Svìer ceuesefj³ee HeÀe@c³etefueMeve keÀer ieesefue³eeW keÀer Hetefle& keÀjves keÀer #ecelee nw~ nce DeðeepesefvekeÀe, HeÀeFpej, yee³ej, SJesefvìme, [eHe´Àe, cesHeÀe, ces Sb[ yeskeÀj, HueerJee, HeekexÀ [sefJeme Jeiewjn keÀes Yeer SHeerDeeF keÀer Hetefle& keÀjles nw~

HetJe& ³eesi³elee SJeb efkeÌueefvekeÀue Hejer#eCe

Svìer ceuesefj³ee GlHeeoeW keÀes efvecee&Ce keÀjves Jeeues nceejs SHeerDeeF Deewj HeÀe@c³etefueMeve HueevìeW

Ipca Contact

API Name Formulation Dosage FormAmodiaquine Tablet 100mg, 150mg, 250mg

Arteether Injection

Artemether Tablets 20mg, 40mg, 80mg, Capsule 40mg, Injection 40mg/ml, 80mg/ml

Beta Arteeter (Artemotil) Injection 150mg/ 2ml

Artesunate Tablet 50mg, 100mg

Artesunate Sterile Injection 60mg/ml

Chloroquine Phosphate Tablet 100mg, 150mg, 250mg, Injection 40mg/ml, 50mg/ml, Suspension 60mg

Dihydro Artemisinin Tablet, Suspension (Under Dev.)

Lumefantrine Tablet 120mg, 240mg, 480mg

Primaquine Sulphate Tablet 7.5mg, 15mg

Proguanil HCLSulphadoxine Pyrimethamine (under development)

Sulphadoxine + Pyrimethamine Tablets 500 + 25mg, 750+37.5 mg

Quinine Tablets 300mg, 600mg

Mefloquine Tablets 250mg

3

Success Story

Prequalification & Clinical Trials

WHO Geneva has approved our API and Formulation Anti-Malarial plants.

In April ’08, Ipca has became the first Indian company and the second company in the world to have WHO prequalification for Artesunate 50mg + Amodiaquine 153.1mg Co-blister tablets.

Future prequalification plans – Artemether 20mg + Lumefantrine 120mg Tablets (dossier submitted) with more dossiers lined up for submission to WHO.

Clinical Trials for Artesunate 50mg + Amodiaquine 153.1mg co-blister have been conducted in Nigeria and Uganda and for Artesunate 100mg + Amodiaquine 300mg fixed dose tablets in Myanmar.

Partnerships

Ipca is the 1st company in the world with whom the Clinton Foundation has signed a partnership agreement for supply of Artesunate 50mg + Amodiaquine 153mg co-blister at a reduced price to the Clinton Foundation Consortium to ensure wider access. We have also signed an agreement for Artemether 20mg + Lumefantrine 120mg Tablets.

To boost our recent entry into New Chemical Entities, we have begun Active partnerships with CDRI (Central Drug Research Institute) – Lucknow , IISc (Indian Institute of Science) and National Institute for Malaria Research.

Range of APIs & Formulations

Ipca has a broad range of Anti-Malarials APIs & Formulations with Strong backward integration by manufacturing most Anti- Malarial APIs to back up formulations.

In addition, Artemisinin based combination therapies (ACT) are actively marketed.

keÀes efJeée mJeemL³e mebieþve efpevesJee keÀer ceev³elee efceueer ngF& nw~ ³en Henueer Yeejleer³e kebÀHeveer Deewj efJeée keÀer Gve kebÀHeefve³eeW ceW mes otmejer kebÀHeveer nw, efpemes Deceesefo³ekeÌJeerve � Deeìeamegvesì keÀes-efyuemìj ìsyeuesì 153 efce. ie´e. keÀes DeHew´ue-08 ceW efJeée mJeemL³e mebieþve keÀer HetJe& ³eesi³elee keÀe ieewjJe efceuee nw~

YeefJe<³e keÀer HetJe& ³eesi³elee Heeves keÀer ³eespeveeDeeW ceW DeeìeaefceLej 20 efce. ie´e.� uegcesHesÀvì^eFve 120 efce.ie´e. ìwyeuesì ([esefpe³ej He´mlegle nes ®egkeÀer nw) kesÀ meeLe ®eej Deewj Yeer [esefpe³ej efJeée mJeemL³e mebieþve keÀes He´mlegle efkeÀ³es peeves keÀer keÀleej ceW nQ~ Deeìeamegvesì 50 efce. ie´e. � Deceesefo³ekeÌJeerve 153 efce. ie´e. keÀes-efyuemìj kesÀ efkeÌueefvekeÀue Hejer#eCe veeFpesefj³ee Deewj ³egieeb[e ceW nes ®egkesÀ nw, peye efkeÀ Deeìeamegvesì 100 efce. ie´e. � Deceesefo³ekeÌJeerve 300 efce.ie´e. kesÀ efkeÌueefvekeÀue Hejer#eCe efve³ele cee$ee ieesueer kesÀ efueS c³eeBceej ceW neWies~

meePesoejer

FHkeÀe efJeée keÀer meyemes Henueer kebÀHeveer nw, efpemekesÀ meeLe efkeÌuevìve HeÀeGC[sMeve ves Deeìeamegvesì 50 efce. ie´e. � Deceesefo³ekeÌJeerve 153 efce. ie´e. keÀes efyuemìj keÀer Hetefle& keÀjves keÀer Yeeieeroejer keÀe keÀjejveecee efkeÀ³ee nw~ Deewj Jen Yeer Ieìer ngF& keÀercele ceW leeefkeÀ efkeÌuevìve HeÀeGC[sMeve keÀvmeesefì&³ece keÀes Fme G®®e keÌJeeefueìer Jeeues Deeìeaefceefmeefveve DeeOeeefjle meefcceÞeCe LewefjHeer (S meer ìer) keÀer He´eefHle nes mekesÀ~

meer[erDeejDeeF (kesÀvêer³e Deew<eefOe DevegmebOeeve mebmLeeve), DeeFDeeFSmemeer (Yeejleer³e efJe%eeve mebmLeeve) leLee veJeerve Deew<eefOe efJekeÀeme kesÀ efueS Yeejleer³e ceuesefj³ee DevegmebOeeve mebmLeeve kesÀ meeLe meefke´À³e meePesoejer ngF& nw~

SHeerDeeF Deewj HeÀe@c³etefueMeve jWpe

FHkeÀe ves meceLe&vekeÀejer efceÞeCe-IeesueeW kesÀ efvecee&Ce mes Svìer-ceuesefj³ee SHeerDeeF keÀes SkeÀ me#ece HeM®eieeceer efve<þe mes HeefjHetCe& efkeÀ³ee nw Deewj GmekesÀ Heeme Svìer ceuesefj³ee SHeerDeeF Deewj efceÞeCe-IeesueeW keÀer efJeMeeue ÞesCeer nQ~

FmekesÀ DeueeJee, Deeìeaefceefmeefveve yesmeJeeueer keÀe@efcyevesMeve LesjHeerpe keÀe Yeer ceekexÀefìbie Meg© nw~

EnrAmB H$m Zm_ {_lU Kmobm| H$s _mÌm H$m ñdê$n

IpcaContact

4

Spreading Wings

On May 30, ‘08, Ipca was launched in a grand ceremony at hotel Delfines Lima in Peru. The day began with a welcome address by Mr. Fernando Hurtado and Ms. Gabriel Granthon followed by an introduction to the history of India. After the brief introduction, the traditional ritual of lighting the lamp was performed by His Excellency, Mr. A. Ramesh, Ambassador of India in Peru, Dr. Amodar Carcelen (Senior Professor of Medicine in Peru), Mr. Shashil Mendonsa (General Manager – International Marketing) and Mr. Mario Koehler (Director of Medigroup).

Mr. A. Ramesh spoke about the Indian Pharmaceutical industry and its development in the recent years. This was followed by a speech by our GM, Mr. Shashil Mendonsa, who threw light on

Ipca’s development in recent years and its future plans.

The same platform was used to launch our first product Zerodol in Peru. Dr. Victor Vallederes (President of the Ortho Association in

Peru and Head of the Ortho Department, Military Hospital)

made a presentation on Zerodol. After the presentation, a Question & Answer session was conducted for the doctors.

Our own Ipca Peru team’s Supervisor, Mr. Fernando Hurtado and Medical Representative, Ms. Gabriela Granthon were the anchors for the launch meeting. The response to the launch was overwhelming. Around 220 doctors, key people from hospitals and chain pharmacies attended the program.

All the invitees were presented with paintings from Rajasthan as a memento. They highly appreciated the program as a unique experience.

The whole event was marked by an Indian touch, right from the decoration of the venue, costumes worn by MRs, Indian cuisine and Indian dance by a group.

The entire Ipca team led by our Country Manager, Mr. Vishant Acharya, worked ceaselessly to ensure that the event would be a grand success. A special mention of Mr. Premchand Godha, Mr. N. Guhaprasad and Mr. Shashil Mendonsa should also be made for their initiative, leadership and constant guidance.

– Rashmi Ravade

The Ipca Peru team is confident of making a big impact in the Peruvian market. We wish them success in all their efforts.

Ipca Peru team (L-R): Mr. Vishant Acharya, Ms. Gabriela Granthon, Mr. Shashil Mendonsa, Ms. Milagros, Mr. Fernando Hurtado, Ms. Irene, Mr. Alexandro,

Ms.Veronica, Mr. Juan and Ms. Jacqueline

Panel doctors (L-R): Dr. Armando Calvo, Dr. Amodar Carcelen (Moderator), Dr. Victor

Vallederes and Dr. Dario Delgado

Lighting the Lamp (L-R): Mr. A. Ramesh, Mr. Mario Koehler and Dr. Amodar Carcelen

It was a remarkable day in the history of Ipca as it created a place for itself on the Peruvian map.

The Ipca Peru team is confident of making a big impact in the

Peruvian market.

International

5Ipca Contact

CPhI, JAPAN 2008

Domestic

July 12, ‘08 marked a remarkable event in the history of 3C Division of Ipca. Our MD, Mr. Premchand Godha and President – Marketing, Mr. M. D. Sharma along with NSM, Mr. Viraj Save, felicitated the 3C Kerala team.

This team became the number one region in India to cross an average sale of more than 76 lakhs and achieve a dream PMPT

of 5.53 lakhs for the period April – June 08.

The felicitation ceremony was organized at Hotel Lake Palace in Allepy. Each member was overjoyed as Mr. Premchand Godha shared a moment and felicitated the Kerala team constituting of 14 PSRs, 3 ABMs, RBM, Mr. Jyothish Kanth and ZBM, Mr. Johnny Edwin. The team was presented with certificates, trophies

and specially designed blazers.

After the ceremony, the team enjoyed a boat ride in the backwaters of Allepy followed by a cultural program and dinner party. So much was the ecstasy among them, by the presence of Mr. Godha that the team has set a vision of crossing a sale of Rs. 1 crore, by September ‘08. Mr. Godha too promised to revisit Kerala and meet them the day they achieve this milestone.

We salute the team for setting an outstanding example of grit and passion for all of us.

– 3C Team

3C Kerala Team Crosses 5 Lakhs PMPT

Standing (L-R): Mr. Sajeev K, Mr. Usman Habeebulla S, Mr. Rahul C. K, Mrs. Remya R., Mr. Vinesh K, Mr. Vimal Kumar V, Mr. Ajeesh T. V, Mr. Sarish P. C

Centre sitting (L-R): Mr. Jyothish Kanth, Mr. Johnny Edwin, Mr. Viraj Save, Mr. Premchand Godha, Mr. M. D. Sharma, Mr. Finson Francis, Mr. Abhijit S, Mr. Sabu Isack

Sitting (L-R): Mr. Vikas M, Mr. Vivek V. B, Mr. Kiran Kumar M. S, Mr. Bhagawal Prasad, Mr. Rajeesh B, Mr. Saljith B. G

InternationalIpca participated consecutively for the fourth time in CPhI, Japan. Staged at Tokyo’s Big Sight Complex, on April 9 to

11, ‘08, the events and seminar/workshop drew over 13,700 attendees. In all, 423 exhibitors from 23 countries were present.Various innovator and generic companies, those including Tonira customers visited our stall and showed keen interest to work with Ipca. Many of Tonira customers who visited our stall showed confidence in continuing business after Ipca took over Tonira. Here are some interesting facts about the Japanese Pharmaceutical market: It is the second largest drug market in the world with an ethical pharmaceuticals market worth almost $65 billion, representing 13% of the world total. Some 1,400 pharmaceutical manufacturing companies employ over 200,000 people and account for 2% of Japan’s total manufacturing output by value.

– Sonali Pandharkar

2nd from right: Mr. Pranay Godha – President API, 3rd from right: Mr. Kamal Bhatia – VP API Exports with Japanese Customers

6

IpcaContact

DomesticActiva: The Fastest Growing Division

Zerodol – the brand in pain-reliever segment has crossed the Rs. 30 crore mark in May ’08. With this achievement, the brand has entered into the big league of our old and well-known brands like Perinorm and Lariago. Every Ipcaite in some or the other way is contributing towards this runaway success of Zerodol.

With such rapid growth, we have taken a lead of more than Rs. 3 crore over our nearest competitor brand Hifenac (from Intas). Not only this, we have surpassed companies like Glaxo, Novartis, Dr Reddy’s Lab, Alkem, Intas, etc., and become the number one company in pain management amongst Orthopedicians.

Zerodol Carnival – An experience of a life time

The robust performance of the brand was celebrated at Bangkok and Phuket from June 17 to 20, ‘08.

This year 55 performers qualified for the prestigious Zerodol carnival. The electrifying performance ensured 6 performers to qualify alongwith the family. The family members enjoyed the event so much that, Ms. Jhule Singh from Rajasthan assured to come for every celebration in the Company by motivating her husband more and more.

Mr. M. Sekhar from ZBM-South Zone was pleasantly surprised to see forty elephants walking through the crowd of five thousand people in the theater of Fantasea show in Phuket. Everyone including VP, Mr. Sunil Ghai missed their families during the event.

The scenic beauty of the ‘PHI PHI’ islands barely allowed AP and Kerala teams to stay away from capturing it in their

cameras. Mr. Tushar Mishra from Orissa tried fruitlessly to capture the beauty of the vast sea in his little eyes during the journey to the island.

We had arranged for the snorkeling event in the deep sea for the Ipca daredevils. This gave us an opportunity to plunge into the deep sea wearing the snorkeling headgear. The Orissa team found it ‘the most thrilling experience in the life’. The entire team was in the deep sea to see the vibrating colors of corals, variety of sea fish and unending marine life.

The excitement reached to its peak when Mr. Manish Khandpekar, GM – Pharma, invited all the members on the dance floor of Choa-praya cruise in Bangkok. Even the tourists from Japan, Europe and France danced with our team to the tune of Zerodol.

The team was so charged up that everybody took an oath not only to join again alone, but with one additional member.

– Amit Kataria

Zerodol touches 30 Crore

Dear Actives,

Activa is 5 years old!

It seems just like yesterday that we started the operation; passionate and focused on our goal of being the best specialty division for Rheumatologists in the country.

Each Active dedication and every drop of sweat has been paid for handsomely. Activa is today Ipca’s fastest growing division and the country’s leading specialty division for Rheumatologists. Not just that, in the last two years our endeavor to repeat Activa’s success with Orthopedicians is also showing remarkable progress. Ipca is the 2nd largest gainer in value in pain management in the last five years. Presently, Ipca has progressed to the 8th rank in pain management, with Activa contributing a substantial portion to this growth. (Source: June ‘08 MAT ORG)

Today, we stand proud as leaders in Arthritis and Pain Management therapies, thanks to Actives’ dedication and

individual effort. We would not be where we are today without them. The respect with which our prescribing fraternity treats us is self evident. Part of the reason is because we don’t sell medicines, we sell complete solutions for felt needs. Whether it is about timely introduction of our brands, or creating initiatives like ‘Arthritis se Aaraam’ and Backbone

of Orthocare, or being the official partners of the International Bone and Joint Decade.

Activa has reached a milestone, and it is right that we pause to celebrate a job well done. Thereafter, set our new horizons. We need to

keep the conquered territory and wrest out further lands for growth. That means consolidating and maintaining our leadership in Arthritis and becoming leaders in Pain Management too.

Congratulations and best wishes to all Actives.

– M. D. Sharma

President – Marketing

7Ipca Contact

Mr. Godha's First IIM Visit It was Ipca management’s novel idea to visit an IIM campus. Our Managing Director, Mr. Premchand Godha,

visited IIM Indore and shared his words of wisdom with the MDP (Management Development Program) participants. We bring to you those cherishing moments.

Standing Front Row (L-R): Mr. S. K. Darh, Mr. Rajesh Bhatewara, Mr. Ashvini Saxena, Mr. Ramdas Chavan, Prof. Ashraf Rizvi (IIM – Indore), Mr. Premchand Godha (MD), Prof. Tapan Panda (IIM – Indore), Prof. Panigrahi,

Mr. Dinesh Siyal, Mr. Chandrasen Hillal and Mr. Alok DaveStanding Middle Row (L-R): Mr. Sunil Kamath, Dr. R. K. Jadhav, Mr. A. F. Jafari, Mr. K. K. Mandwaria,

Mr. Prakash Nayak, Mr. R. W. Doifode, Mr. Bhupendra Joshi, Mr. P. P. DubeyStanding Last Row (L-R): Mr. Dhanesh Singhai, Mr. A. R. Narayanan, Mr. Unnikrishnan Menon,

Mr. Suryakant Pai and Mr. A. K. Choubey

It was a great moment for all the twenty MDP (Management Development Program) participants of Ipca when our MD, Mr. Premchand Godha, visited them on June 6, ‘08.

Mr. Godha addressed the participants and the senior faculty members about his over 32 years’ journey with Ipca, and the challenges and hurdles he faced. His very presence and the inspirational speech set a high level exuberance across all participants, who shared their concerns, expectations and also pledged their enhanced contribution and support in making his vision come true.

While elaborating on the criterion for the selection of the individuals for this Management Development Program, Mr. Godha expressed his expectations from the individuals and their collective effort in adding value to the work. He proved his point with some examples of those who have been with the company for a long time and have contributed, with a difference.

The participants wholeheartedly thanked Mr. Godha for his visit and for the opportunity given to them, in recognition of their loyalty and performance.

At the end, the twenty participants from Ipca's senior management team, having sharpened their skills with the knowledge gained through the program, were all charged up to make a difference in their respective work areas.

– Ashok Sharma

Human Development

Mr. Premchand Godha, MD – Ipca (right) with Prof. Tapan Panda (IIM – Indore)

IpcaContact

8

Ipca Excels in INSSANIpca recently participated in a national summit represented by eminent industries. As one of the leading pharma

companies in India, Ipca presented some case studies and success stories and took away many awards. To know more, read on…

‘National Suggestion Summit’ is a yearly event organized by the ‘Indian National Suggestion Scheme Association’ (INSSAN). This is a key event for various types of industries such as Manufacturing, Service and public/private sector undertakings from all parts of India.

The year 2008 had a special significance of being the 10th year of the Summit. It was organized on May 23 and 24, ‘08 by INSSAN Northern Indian Chapter (NIC). The venue was the PHD Chamber of Commerce & Industry, Delhi.

With a theme of ‘Competitiveness through Employee Involvement’, the summit was divided broadly in various categories as follows:

Slogan Competition

Poster Competition

Essay Writing

Technical Paper Presentation

Case Study Presentation

Breakthrough Innovations/Success Stories

This is for the third time Ipca has made a mark in this summit by presenting five case studies and one breakthrough innovation case. These studies have been contributed by Athal, Aurangabad, Indore, Ratlam and Exon, Mahad plants based on quality and merit of the cases. Here’s a review:

Plant: IndoreTopic: Loss of Production due to Frequent breakdown and leakage in Cyclization reactor limpet coilPresented by: Mr. C. S. Soni

Plant: Exon, MahadTopic: Low Conversion (yield) of Losartan Base from Intermediate 90% against theoretical conversion No Recovery of MDC for recycling in process High product cost.Presented by: Mr. M. Rehman

Plant: AthalTopic: Not able to meet production target of Ibuprofen 400mg tablet (F6) due to low Output & Quality Problem.Presented by: Mr. Manohar Kuwar

Plant: Makers Dombivali

Topic: Low yield of product N-N Diethyl Ethylene Diamine. High cycle time due to slow distillation.Higher consumption of Caustic Soda Flakes.Presented by: Mr. R. N. Attarde

Plant: RatlamTopic: Short time to supply CQP 600mg + CQP 300mg + Primaquine 45mg combi-pack tablets to Govt. tender supply.Presented by: Mr. Nandji Singh(B) Breakthrough Innovation/Success Stories

Plant: RatlamTopic: Journey of success of national energy conservation award 2007Presented by: Mr. K. K. Ajmera

Mr. M. Rehman of Exon Mahad receiving the third position award from Mr. Yogesh Munjal, Chairman – INSSAN-NIC & MD – Munjal Showa Ltd.

Mr. Attarde, Mr. M. Rehman and Mr. K. K. Ajmera, participating in the Quiz contest

Human Development

Ipca Contact

9

Exon-Mahad plant employees were highly excited and thrilled about this achievement.

They extended a warm welcome to Mr. M. Rehman on his arrival on May 26 at the plant.

This is for the third time Ipca

has made a mark in this summit by presenting five

case studies and one breakthrough innovation case.

The Summit had representation from many eminent companies, namely, Bharat Electronics Limited, BHEL ESCORTS, Godrej Consumer Products, Hero Honda Motors ltd, IFFCO, ITC, Kirloskar Auto, Krishna Maruti, Life Long Sciences, Mahindra & Mahindra Ltd., Maruti Suzuki, Munjal Showa, NTPC, Reliance Industries, Shriram Pistons Rings Limited, Sona Koyo Steering, Sterlite, Tata Motors, TVS Motors, etc.

Around 264 delegates from more than 57 organizations attended the summit. It was an enlightening experience for both the participants and the organizers to witness 110 Suggestion Case Studies which were presented. In addition, there were 12 presentations in the category of Technical Papers and Unique EI Practices. That was not all, the summit had much more in store for everyone. Extempore debates,

quiz program, On-the-spot Suggestion Contest were some of the special features of the event.

All the efforts put in by the participants were recognized through various awards and prizes. Take a look at who’s achieved what.

Mr. M. Rehman of Exon, Mahad won the 3rd award in case study presentation for ‘Low Conversion (yield) of Losartan Base from Intermediate 90% against theoretical conversion’.

Special prize was given to Mr. Nandji Singh of Ratlam for his inspirational and impressive presentation of his case study.

Participation certificates and trophies for all case study presentations.

Quiz participation prize given to Mr. K. K. Ajmera, Mr. M. Rehman and Mr. Attarde.

– Ashok Sharma

Mr. M. Rehman being greeted by plant employees

Mr. Nandji Singh receiving Special appreciation prize from Mr. V. K. Srivastava, Hon. General Secretary-INSSAN-NIC

(From L-R): Mr. K. K. Ajmera, Mr. D. P. Anjne, Mr. Rehman, Mr. V. K. Srivastava, Hon. General Secretary – INSSAN-NIC,

Mr. Ashok Sharma and Mr. Nandji Singh

Human Development

IpcaContact10

Cricket FervorCricket, the gentleman’s game, was played with a true spirit by our energetic Ipcaites.

We bring to you those capturing moments.

was grabbed by Mr. Kishore Pednekar (Merck) for his all round performance.Ipca has continued its tradition of good performance in this tournament… And is still one of the most respected teams. In the end, the better team has won.We reassure our team that they have indeed made us proud by putting up such a spirited performance. We eagerly look forward to the E–Merck trophy next year.

– Nishant Ayare

On April 26, ‘08, in the finals of the E–Merck trophy, Ipca took home the runners-up trophy. Batting first, Ipca scored 184 runs for eight wickets in 45 overs. Mr. Hemant Tawde played a captain’s innings by scoring a glorious half-century. With no other noteworthy contribution coming forth from our batsmen, Merck succeeded in restricting Ipca to a reasonable score.Merck started off with a poor opening, but the third wicket partnership added 98 runs, threatening to make the match a one-sided affair. However, the advent of our MD, Mr. Premchand Godha, on the field inspired our players.Once again, a gutsy display of hostile fast bowling by Mr. Tawde (4 wickets for 34 runs) saw the Merck wickets tumbling. However, their eighth wicket pair managed to hold on and took their team to the winning front by scoring 185 runs for 8 wickets in 42.5 overs.The match was played in good spirit and a sense of camaraderie. The presentation ceremony was graced by the Managing Directors of both the companies and other senior dignitaries. This year, Ipca had to be contended with the Runners-up trophy.The ‘Batsman of the tournament’ award was given to Mr. Rohit Bhalla (Merck) while the ‘Man of the match’ award

At times, when we are going through a period of stress, it’s important to make a special effort to relieve ourselves mentally, physically and emotionally. Ipca has a solution to this. Find out more…

“I play chess like carom…” Yes, we would love to be innovative and creative…but certainly not to this extent. This is just on a lighter side.We talk so much on finding ways to de-stress ourselves, i.e., by practicing yoga or taking a break from routine. But we fail to find time once back home from a hectic day. Keeping this in mind, we inaugurated a facility for our

employees called ‘In-door games’. The activity started with players striking coins and moving pawns in their first game. To stress more on de-stressing, carom, chess and dart boards were ordered initially. This is just the beginning, more items would be added once we receive more suggestions from people. Till then, happy playing!

– Niveditha Rai

A Sporty Way to De-stress

Human Development

The cherishing moments shared with Sachin Tendulkar during the practice session

Ipca players at their best

Ipca Contact11

We are pleased to announce the promotion of Mr. D. K. Singhai, General Manager Formulations, as Sr. General Manager – R&D (Formulations) and his transfer from Ratlam to Mumbai with effect from April 1, ‘08.Consequent to his transfer to Mumbai, Mr. Singhai will report to Dr. Y. K. Bansal, President – R&D (Formulations) and will be directly responsible for the following: Development of new products for all Divisions of Domestic Market Improvisation on existing products Technology Transfer Systems and procedures improvisation (Documentation, QA activities within the department, etc.)Let us all join in wishing him every success in his new assignment and extend all co-operation.

Welcome to Mumbai

A Big Applause to...Ms. Geeta S. Naik is a sincere, hard working, self motivated girl. She is at present working as Manager in Medical Affairs and Clinical Research Department, under Dr. Anil Pareek, Sr. VP, Medical Affairs and Clinical Research. She has been with Ipca for the past 14 years. It’s rare to find such commitment and dedication to an organization in this era of short tenure jobs.Geeta was focused on education right from the beginning. She was a scholar throughtout her schooling days. In HSC, she came first in the college. After completing B. Pharm, she wanted to pursue M. Pharm. However, due to financial reasons, she could not do so. Getting a job was her first priority. She therefore opted for Apprenticeship in Glaxo India Ltd. In this one year training, pharmacy graduates are exposed to all aspects of drug manufacturing process. She used her first salary (A stipend of Rs. 800/-) to get first Diploma, i.e., Diploma in Computer Programming. At that time knowledge in computers was not a must in a job, but she had the foresight that in times to come, knowledge in computers would be an essential prerequisite.Next, was a call from Ipca for a Trainee post in Medical Services Department. Computer knowledge was the foremost requirement. Her first Diploma now came to use.She completed her second Diploma in Computer Science, which involved various computer languages such as C, COBOL, BASIC, etc., in the first grade.It was at this time, she thought that a Management course is a must, if one has to make progress in one’s career. She thus did her third Diploma in Business Management. On completion of her trainee period, she became Jr. Officer and her main job was of documentation, including literature search.Seeing Geeta’s capabilities, her senior gave her the responsibility of Medico Marketing, wherein she prepared Product Manuals, Product Monographs, Medical Slides, etc. Her close association with Marketing led to her fourth Diploma in Marketing Management. Geeta’s effective communication skills brought her an opportunity of training the field force in medical aspects of

the products. She handled all the activities of the Medical Services Department.Later on, she thought of doing her fifth Diploma in Industrial Management, which focused on all the aspects of managing an entire industry.As Jr. Executive (after her promotion), her active participation in Ipca’s In-house magazine ‘Contact’ from year 1995 to 1997, made her pursue an MBA degree with specialization in Marketing, which she felt was more important than a Diploma. This was her second Degree after B. Pharm which she

completed successfully.Since the Medical Service Department also extended medical support to the Export Department, she thought of having some knowledge on export related work. This led to her sixth Diploma in Export and Import Management. She stood first in the EXIM Examination held by the Indian Merchant’s Chamber and got as many as six awards for her performance.Ipca was just entering the clinical research area and Geeta was extensively involved in clinical research of two blockbuster molecules of Ipca, i.e., Hydroxychloroquine and Aceclofenac. Most of the trials in which she was involved have been published in the international medical journals. For her efforts in Aceclofenac Trial, she was given a Performance Award by the Company.To ensure that all aspects of Schedule Y of Drugs and Cosmetics Acts and Rules are being followed in Ipca, she felt the need to undergo training in Regulatory Affairs. Thus came her seventh Diploma, i.e., Postgraduate Diploma in Pharma Regulatory Affairs. After being promoted to various positions, she now works as Manager in Medical Affairs and Clinical Research Department.Apart from the educational courses, she also did a five year course in Bharat Natyam from Poorna Prajna Education Centre.She has been given the additional responsibility by our MD, Mr. Premchand Godha, of setting up the Corporate Pharmacovigilance Cell under Dr. Anil Pareek. When we asked her what would be her next Diploma, she immediately said, “Diploma in Pharmacovigilance”.

Human Development

Meet our ColleagueMr. D. K. Singhai

Ms. Geeta Naik

P o w e rW o

r d I

IpcaContact

Welcome

Mr. Abhay R. Katikar General Manager – QC,

Mumbai

Ms. Bela S. BarveDGM – Marketing, (Intima), Mumbai

Mr. Bhikhabhai B. PatelSr. Manager – R&D (FRM),

Mumbai

Mr. Manoj Kumar Sharma Sr. Product Manager – Exports, Mumbai

Mr. Satish D. DhandekarVP – Sales & Marketing,

(Intima), Mumbai

Mr. G. GopakumarBusiness Development

Manager – Exports, Mumbai

Mr. D. L. KhokhaniSr. Manager – Tech

Transfer, R&D, Ratlam

Mr. Vijay Kumar Kashyap Manager – QC,

Dehradun Unit 1

We are pleased to inform you that Mr. Dharmendra Singh's thesis has been approved and accepted by the University of Mumbai. He is now eligible for the degree of Doctor of Philosophy (Science) in Chemistry.

Congratulations

12

IncognitoPronunciation: [in-kog-nee-toh, in-kog-ni-toh]Function: AdjectiveMeaning: Having one’s identity concealed, as under an assumed name, especially to avoid notice or formal attention.

IslePronunciation: [ahyl]Function: NounMeaning: A small island.

InurePronunciation: \i-nur, -nyur\ Function: VerbMeaning: To make less sensitive, to become advantageous

InsipidPronunciation: [in-sip-id]Function: AdjectiveMeaning: Without distinctive, interesting, or stimulating qualities; vapid: an insipid personality.

Doctor!

Human Development

Ipca Contact

Welcome

13

We have bagged the D&B – ECGC Indian Exporters Excellence Award – Topmost Exporter in the front-runners of Pharmaceutical Large Scale Sector on June 2, ‘08 at Hyatt Regency, Mumbai.

Since the era of liberalization, Indian exports have emerged as one of the significant components in bringing a positive change to the country’s economy. The sustained growth of over 20% in the last few years has exceeded the forecast and has made the Indian export market realize its true potential.

Recognizing this dynamic growth spirit of the Indian exports, Dun & Bradstreet India (D&B India), in association with Export Credit Guarantee Corporation of India Limited (ECGC), have come up with a new concept to appreciate the topmost exporters in the front-runners of pharmaceutical large scale sector. And this year, our company was awarded the Excellence Award.

The occasion was graced by chief guest, Mr. G. K. Pillai, IAS, Secretary, Department of Commerce, Ministry of Commerce & Industry, Government of India.

On behalf of all Ipcaites, our Executive Director, Mr. A. K. Jain,

Crowning Glory

received the award from Mr. A. V. Muralidharan, Chairman & Managing Director, ECGC and Dr. Manoj Vaish, President & CEO – India, Dun & Bradstreet.

Congratulations to the Export Logistic Department on their success.

Ipca bags the Topmost

Exporter Award!

A proud moment – Mr. A. K. Jain receiving the award

Fifth Clinical Trial publishedOne more clinical trial of Ipca entitled ‘Clinical effectiveness of low dose chlorthalidone (6.25mg) – atenolol combination in stage I hypertensive patients: a multicentric, randomized, controlled study’ has been published in the ‘Current Medical Research Opinion’ (Curr Med Res Opin 2008; 24(6):1773-1782). This being the fifth clinical trial publication

by Ipca, is an achievement in itself.

This is the first study to demonstrate safety and efficacy of low dose chlorthalidone (6.25 mg) in hypertensive patients. The study was conducted on 300 patients with stage I essential hypertension at four leading medical institutions of the

country, namely, LTMM College and LTMG Hospital (Mumbai), Seth GS Medical College and KEM Hospital, (Mumbai), Indira Gandhi Medical College (Nagpur), Grant Medical College and St. George Hospital (Mumbai).

Findings of our study demonstrated that a combination of chlorthalidone 6.25mg with atenolol 25mg is safe and as effective as the widely used combination of atenolol + amlodipine as well as high dose atenolol (50 mg). This low dose of chlorthalidone could further reduce dose-related concerns of metabolic adverse effects and may lead to wider usage of this proven anti-hypertensive agent in combination therapy.

Based on the results of this study, combination of low dose chlorthalidone (6.25mg) with atenolol 25/50mg has been approved in India by DCGI.

NEWS

IpcaContact14

To consolidate its presence in the Active Pharmaceutical Ingredients (APIs) space and to diversify its products portfolio, Ipca acquired Tonira Pharma through open offer to the shareholders. The acquisition was completed by Ipca recently by acquiring 37.27% controlling stake in Tonira. In the board meeting of Tonira held on May 3, ‘08, Ipca took the management control and

Mr. R. K. P. Verma was appointed as Managing Director of the company.

Tonira Pharma Ltd established in 1989, is a 100% Export Oriented Unit. The company is in the business of manufacturing and marketing APIs and Intermediates and has the state-of-

the-art manufacturing facilities at Ankleshwar and Nandesari approved by WHO GMP.

The R&D Centers of Tonira Pharma Ltd are equipped with modern instruments and recognized by DSIR, Govt.

Ipca acquires Tonira

of India. With a strong presence in anti-rheumatic, anti-depressant and anti-peptic ulcerant therapeutic segments, the Company exports to more than 40 countries with a net sale of 8 million US dollars. The company has established its tie-up with international companies for contract manufacturing and API development.

The company’s Nandesari manufacturing facility, which was inspected by the team of USFDA investigators on February 26 to 28, ‘08, has got the approval from USFDA. This would give a boost to the company’s exports to regulatory markets. With the combined marketing efforts of Ipca and Tonira, supported by a strong technical team of Ipca, the company is poised to grow exponentially in exports.

Success is the good fortune that comes from aspiration, desperation, perspiration and inspiration… We have proved this once again by achieving one crore units in continuity for the month of April 2008. It is due to the efforts and team spirit of all Ipcaites at Dehradun that we are achieving this momentum.

We wish that this zeal and enthusiasm continue with each day and we break the barrier of 1.5 crore units in the year 2009.

A Milestone Achievement (Dehradun)

Ipca has received approval from the US Food and Drugs Administration to manufacture Propranolol Hydrochloride Tablets USP 10mg, 20mg, 40mg, 60mg and 80mg for the US market. The total annual market sales for Propranolol Hydrochloride tablets in the US were $ 24.1 millions (IMS-MAT: December 2007).

This is the first product approval received by Ipca for a product manufactured from its Piparia (Silvassa) Formulations manufacturing unit after the said unit’s pre-approval inspection recently by USFDA.

USFDA Approval for Propranolol Hydrochloride TabletsIpca will manufacture this formulation for the US healthcare system from its Piparia (Silvassa) Formulations manufacturing unit using Ipca’s own DMF approved Active Pharmaceutical ingredient (API) – Propranolol Hydrochloride.

Ipca has set up a new formulations manufacturing facility meeting the US regulatory requirements at SEZ – Indore. The commercial production from this facility is expected to commence from the 2nd half of the financial year 2008-09.

Nandesari

Ankleshwar

News

Mr. R. K. P. Verma

Ipca Contact

15

RatlamIpca, Ratlam was audited by World Health Organization, Geneva from

February 11 to 14, ‘08.Based on the audit observation compliance report submitted, WHO confirms that Ipca, Ratlam is approved by the authority on May 21, ‘08. This is for the third consecutive time that Ipca, Ratlam has got approval from WHO. Three Cheers!

On March 27 and 28, 2008, our Ipca, Dehradun was audited by the WHO team and was later issued the certificate on May 9, ‘08.

Dehradun

Ipca’s Piparia manufacturing facility has successfully completed the USFDA audit without any 483s. The FDA audit was conducted from April 14 to 17, ‘08. This is the first formulations plant of Ipca audited by USFDA. The USFDA inspection team was pleased with the systems followed by Ipca and appreciated the enthusiasm shown by the Ipca members.

Piparia

Colombia Invima Audit was conducted at Ratlam from April 28 to May 2, ‘08. On the last day of the audit, the authority approved our Ratlam Formulations facility.

Ratlam

We congratulate all Ipcaites involved on their hard work and efforts put in to make

this audit a great success.

The last quarter had seen audits being conducted at most of our sites. Here’s a review…

A Quick Review News

The Pharmaceutical Medical Devices Agency (PMDA) audit was conducted at Ipca, Ratlam from May 20 to 22, ‘08. This is the first audit faced by Ratlam API team from Japan Authorities. The audit was completed effectively without any critical, major or minor deficiencies.Now, our facility is approved and accepted by all the topmost Regulatory authorities worldwide, i.e., USFDA, EDQM, TGA, WHO (GENEVA), Danish Medicines Agency (EU authority, Denmark) and PMDA. This approval has indeed added one more jewel in Ipca’s crown.

Ratlam

It was for the first time that Ipca faced a Regulatory Authority from a major Asian country, i.e., Korean Food & Drugs Administration (KFDA) in November 2007. This audit focused on cGMP compliance according to ICH Q7 & KFDA guidelines.

Ipca Ratlam API facility was inspected by USFDA in April ‘08. The USFDA audit was cleared without any 483 observation. This was the third successive achievement for Ipca Ratlam API facility to clear the USFDA inspection without any non-conformance observations.

IpcaContact16

Ipca Laboratories Limited has incorporated a new Company called ‘Ipca Traditional Remedies Pvt Ltd. (Ipca TR)’ in association with the renowned ayurvedic physician, Vaidya Balendu Prakash, Founder Director of Vaidya Chandra Prakash Cancer Research Foundation (VCPCRF), Dehradun.

Ipca TR will promote evidently effective and protocol based ayurvedic treatment for certain types of cancer and chronic diseases through proficiently trained ayurvedic physicians under its brand ‘Padaav-Speciality Ayurvedic Treatment Center’. Simultaneously, Ipca TR is soon going to launch four ayurvedic formulations developed jointly by R&D of Ipca Labs and VCPCRF (SIROs).

Ipca TR aims to bring stated efficacy of ayurveda into mainstream medicine by combining traditional knowledge with technology and innovation. It has constituted working groups of various disciplines from Ipca Labs – Mumbai, VCPCRF and Bharat Bhaishajya Shala Pvt. Ltd, Dehradun, under the visionary guidance of Mr. Premchand Godha and Vaidya Balendu Prakash, Promoter Directors of Ipca TR.

In the above background, Ipca TR has set up its first indoor ayurvedic hospital (Padaav) consisting of 54 rooms built on a two-acre land in the lush green surroundings of Versave on the Western Express Highway, District Thane, Maharashtra. This unit will serve the following purposes:

IPD/OPD (In-door/Out-door Patients) by Vaidya Balendu Prakash and his team for the treatment of certain forms of cancer (the treatment depends upon the type, stage and age of the patient. Ayurvedic treatment is decided after seeing the report of the individual patients at Padaav) and chronic diseases with main emphasis on:

Acute Promyelocytic Leukemia (fresh/relapse cases)

Chronic Migraine

Chronic Nasal Allergies and Sinusitis

Chronic Relapsing Pancreatitis

Childhood Asthma

Multiple Sclerosis

Ayurveda is the world’s oldest health care system. With the rising popularity and proven benefits, many pharmaceutical companies, who until now were involved in the manufacturing of allopathic drugs, have forayed into this market segment.

We are one among them.

Healing Cancer the Natural Way

Endorsement and appreciation

This is the strongest evidence I have seen of the efficacy of any Indian indigenous medicine in the treatment of Cancer. I strongly recommend that a prospective clinical trial be conducted as per ICH GCP guidelines to confirm these findings. I will be happy to provide my expertise, help design as well as participate in such a study.

Dr. Purvish Parekh(HOD Oncology, Tata Memorial Hospital,

Mumbai)

Dr. Balendu Prakash has done a commendable job in this field regarding the treatment of APML through metal-based Ayurvedic formulation. The data generated reveals that this Ayurvedic formulation is effective and potentially safe for treatment of APML and I hope that this drug may open new armamentarium in the field of oncology during the coming years.

G. S. Lavekar, Director CCRAS,

Dept. of Ayush

It’s actually an acceptance by both the people, i.e., Vaidya Balendu Prakash and Dr. Anish Maru. Both the systems have something in common which they have observed. And all the scientific observations which are done should be put in a record and must be published. It is like doing a service for the society.

Dr. P. M. Shah (Director of Gujarat, Cancer and

Research Institute)

Ayurveda

Source: City Cheers (Vol. II Issue: 7 July 2008)

A practicing ayurvedic physician, Founder Director VCP Cancer Research Foundation (SIROs), Member – Program Advisory Committee, National Cancer Control Program, MOH & FW, Govt. of India, Member Governing Body, CCRAS, Dept. of Ayush, MOH & FW, Government of India, Advisor Ayurveda, Government of Uttarakhand, Member – Indian Co-operative Oncology Network (ICON), and International Headache Society, UK.

He is a recipient of the National Civilian Award Padmashri (1999) from the President of India.

Vaidya Balendu Prakash

17Ipca Contact

Acute Promyelocytic Leukemia (APML)

APML also termed as AML-M3, is a variant of acute myeloid leukemia (Blood Cancer). It is often associated with serious coagulation abnormalities. Due to its hemorrhagic nature, most of the time, a patient may die during the process of diagnosis itself. Intense and frequent transfusions, hygienic condition and combination of ATRA with chemotherapy bring remission to a fair number of patients. However, more than fifty percent patients of APML experience relapse of the disease and succumb to causality most of the time. There are a few cases that cannot continue with conventional modern medicines due to hematological or non-hematological side effects, high cost of anti-leukemia treatment and supportive care. This causes high mortality among such cases.

A pilot study on ‘Effect of Metal Based Ayurvedic Formulations in the Patients of Acute Promyelocytic Leukemia’ was sponsored by Central Council of Research in Ayurveda and Siddha (CCRAS), Department of Ayush, Ministry of Health and Welfare, Government of India. The patients who were followed for three years after ayurvedic treatment showed complete recovery from the APML.

As a result, National Research Development Corporation (NRDC) has obtained the US and European patents against the said invention. At this moment, ayurvedic treatment for APML is available in Mumbai, Bangalore and Dehradun.

Since 1982, till date, data of all enrolled patients of APML is meticulously collected and analyzed. It reveals the Ayurvedic Treatment Protocol (AYTP) for APML has following survival rates:

De novo (freshly diagnosed) and treated with AYTP – 91%,

Relapse (treated with anti-leukemic modern medicines, achieved remission but disease reappeared – 65%,

Defaulter (anti-leukemic treatment could not be continued due to side effect/ cost) - 77%, and

Post remission (disease free) – 87%, The first patient, who was treated as De novo case of APML in December 1982, has completed more than 25 years disease free survival. AYTP does not cause any noticeable side effect.

Migraine

Migraine is the most common form of headache with high prevalence in urban population and developed countries. About 15-17% of women and 5-7% of men

are affected by this disorder. Though migraine may occur in all age groups, it is highly prevalent in the age group of 18-45 years. It affects more women than men. Migraine attacks are characterized by recurrent headaches, unilateral/bilateral positions, pulsating in nature with moderate to severe intensity causing debility. Therefore, migraine has been ranked 19 among the debility causing diseases

by World Health Organization. There is no known cause and cure for migraine. Though diverse theories are brought forward time to time by experts, none of these are able to provide long-term prophylactic treatment. On the contrary, the prolonged use of painkillers further triggers the Medication Overuse Headache (MOH) or other side effects. In the above background, the ongoing results obtained from the multiple Ayurvedic clinics trained at VCPCRF and Ipca TR Pvt. Ltd. in Bangalore, Mysore, Tumkur, Bellary, Shimoga and Hubli (Karnataka), Aurangabad, Mumbai (Maharashtra), Warangal, Hyderabad (Andhra Pradesh), Meerut (Uttar Pradesh) and Dehradun (Uttarakhand) and previous results of the first prospective study at Chandigarh conclusively prove that Ayurvedic therapy (AYT) is significantly effective in the prevention and treatment of Migraine. Vaidya Balendu Prakash’s innovation in the treatment of migraine is rapidly attracting the attention of the scientific community.

About four years back I came to know that my wife was suffering from cancer. We treated her in all the specialized hospitals like Tata Memorial Hospital (Bombay), AIIMS (Delhi), Cancer Research Institute (Gujarat), but all in vain. Even the experts from Tata Memorial Hospital informed us that she can only survive for a maximum of two months and if so, that too on bed. Then somebody in Ajmer told us about Vaidya Balendu Prakash. We went to him and the result is in front of everybody. It’s been three and a half years she is fine with his treatment. According to me it is one of the best treatments in the world and he is like a God serving the people.

- Mr. Mannan Hussain, M. P., Lok Sabha

Endorsement and appreciation

The allopathic treatment involves around Rs. 10 lakhs and can be higher, with serious side effects. There is no surety of complete cure, as it has been seen that 50 percent of such cases relapse.

Dr. Anish Maru, Senior Consultant Haemato-Oncologist Director, Searol Sameer Centre: Born on October 26, 1968 in Jaipur, he has done MBBS and MD (General Medicine) from SMS Medical College, Jaipur. Thereafter he did his DM in Medical Oncology from Bangalore and then settled in Jaipur to serve the state, as no specialist was available in Rajasthan. He is a pioneer in spreading the concept of Oncology, in and around Rajasthan. He came in contact with Vaidya Balendu Prakash at a meeting in Baroda, where he got convinced with his data and started sending his patients of APML who got cured. Dr. Anish Maru started his own cancer center, SEAROC at S. K. Soni Hospital, Jaipur in 2006, when Vaidyaji contacted him for establishing an Ayurvedic Leukemia Treatment Clinic. ALTC was established on April 13, 2007 in the presence of Honorable CM, Vasundhara Raje.

Read more about APML and migraine at www.padaav.com

Source: City Cheers (Vol. II Issue: 7 July 2008)

IpcaContact

18

NewsWHO prequalifies Ipca Laboratories’ Anti-Malarial Formulation

Ipca is the second company in the world and the first Indian company to receive this prequalification.

The World Health Organization (WHO) has prequalified Ipca’s anti-malarial formulation of Amodiaquine+Artesunate Co-blister making. With this, two of Ipca’s anti-malarial formulations are prequalified by WHO Geneva, out of the total of five anti-malarial formulations prequalified by WHO and one is currently under evaluation.

Ipca is India’s market leader in anti-malarial and also the largest manufacturer of anti-malarial APIs (Active Pharmaceutical ingredients, i.e., Bulk Drugs) and Formulations in India. Ipca has active partnerships with CDRI (Central Drug Research Institute), IISc (Indian Institute of Science) and National Institute for Malaria Research for a new anti-malarial drug development.

On this historic occasion, our MD, Mr. Premchand Godha said, “We are happy about this development and this prequalification only reiterates the quality, safety and efficacy standards Ipca sets for itself. WHO has set exceptionally high and stringent norms to meet its standards and we are proud to consistently meet them.”

“Ipca prides itself on being the market leader in anti-malarials with 32% market share and it’s probably the only major company in India to launch a separate domestic marketing division for anti-malarials. This (prequalification) also underlines the vast experience Ipca has in this segment, i.e., 33 years in manufacturing and marketing anti-malarial formulations and over 23 years in anti-malarial APIs.”

About WHO Prequalification

The Prequalification Program set up in 2001, aims to increase access to priority medicinal products that meet unified standards of acceptable quality, safety and efficacy, currently focusing on those medicines used for treatment of diseases such as Malaria.

Each manufacturer, who wishes their medicines to be included in the prequalified products list, must present extensive information on the product/s, submitted to allow qualified assessment teams to evaluate its quality, safety and efficacy. The manufacturer must also open its manufacturing sites to an inspection team which assesses working procedures for compliance with WHO Good Manufacturing Practices (GMP).

The manufacturer provides a comprehensive set of data about the quality, safety and efficacy of its product, including details about the purity of all ingredients used in manufacture, data about finished products, such as information about stability and the results of in vivo bioequivalence tests. The assessment teams evaluating the products include experts from some of the national regulatory authorities of the European Union as well as from Canada and Switzerland. These teams ensure that high quality, international standards are respected.

Prequalification draws from the expertise of some of the best national regulatory authorities to provide a list of prequalified

products that comply with unified international standards. This is why, both in 2002 and 2004, the International Conference of Drug Regulatory Authorities (ICDRA), made up of more than 100 national medicines regulatory authorities, made a formal recommendation that ‘WHO should continue the prequalification project of medicines for priority disease programs, particularly for HIV/AIDS, malaria and tuberculosis’.

The list of prequalified medicinal products is used principally by the United Nations agencies including UNAIDS and UNICEF to guide their procurement decisions. But the list has become a vital tool for any agency or organization involved in bulk purchasing of medicines, be this at country level or at international level, as demonstrated by the Global Fund to fight diseases such as Malaria.

More About Ipca

Ipca is a vertically integrated company, manufacturing and marketing Formulations, APIs and Intermediates. It’s the 2nd largest Wealth Creator in the Indian Pharma Industry and among the Top 10 Pharma Exporters from India. In 2007-08, total turnover has crossed the historic landmark of Rs.1000 crores with exports to over 105 countries. It has featured four times on the Forbes list of ‘Top 200 Best Under a Billion Companies outside the US’.

The API and Formulation plants manufacturing anti-malarial are approved by WHO Geneva. Major regulatory authorities like USFDA, UK MHRA, TGA Australia, MCC South Africa, etc., have also approved the API and Formulation Plants. Strong backward integration by manufacturing over 55 APIs helps cut costs and ensure steady supplies for a broad range of formulations.

Two separate R&D teams of Formulations and APIs with over 200 scientists are focused on development of APIs, Non-infringing routes, Novel Drug Delivery Systems (NDDS), Novel dosage forms, etc. Over 30 formulation product dossiers have been approved by regulatory authorities of the USA, UK, Australia, New Zealand, Portugal, Hungary and South Africa, with a strong product pipeline in place.

Anti-malarial sales at 200 crores constitute around 20% of the total turnover. Ipca is also one of the world’s largest manufacturers of Artemisinin-based APIs and formulations and Chloroquine Phosphate and also oversees cultivation of the Artemisinin crop in various states.

Ipca is committed to the cause of helping to save one million lives which are lost due to Malaria and Ipca has launched ‘Mission Malaria’ and partnered with like-minded organizations. On the 1st World Malaria Day, it announced a joint initiative with leading diagnostic service provider, Metropolis Health Services and leading pest management company, Pest Control India to form ‘Fight Malaria – Making it Possible’, a unique 360 degree initiative to combat Malaria.

19

Ipca Contact

NewsA unique 360 degree approach to fight Malaria

Metropolis, Ipca and PCI join to form “Fight Malaria - Making It Possible”

Commemorating the world’s first ever World Malaria Day, three leading companies — Metropolis Health Services, Ipca and Pest Control of India, from different arenas, yet bound by a common objective of defeating malaria have joined hands to form Fight Malaria – Making It Possible. The primary objective of the foundation is to spread awareness of the disease, help control the problem and provide expert solutions to eradicate and fight the menace.

The companies involved in the mission are leaders in providing anti-malarial solutions across 3 different arena for providing leading pest management, expert diagnostics and anti-malarial drugs, hence forming a unique 360 degree approach in tackling the menace. Metropolis is a leading corporatised diagnostic firm since 1981, Ipca is the market leader in anti-malarial drugs in India since 1969 and PCI is a leading pest management company since 1954. The tagline, ‘Making It Possible’, was derived from the initials of each company.

The respective spokespersons of the three organizations were ecstatic to share the foundation day of the association with the first ever World Malaria Day, a day incorporated to provide effective control and measures of malaria around the world.

On this occasion, Dr Sushil Shah, Chairman, Metropolis Health Services said, “World over, this is the first time ever the anti-malaria day will be celebrated and we are proud to be part of this mission. We were finding ways, methods of doing and coming up with something unique and different on this day, hence we choose to form an association exclusively for malaria. We are indeed delighted and honored to be part of this mission which will not only help save lives but will also promote wellness in our society. Through our foundation we wish to enhance awareness about cause, prevention and treatment among the target communities and healthcare service providers through information, communication and education.”

Mr. Prakash Shanware, President-HR, Ipca commented, “Every year in the pre-monsoon period during the month of June, people are struck with malaria across socio-economic groups. The disease poses a major threat not only to people in our respective cities but also presents the greatest health hazard for tourists visiting different regions in our country. Through our foundation we aspire to create community awareness and promote people’s participation in malaria control. The foundation aims to kick start the campaign during this season through educating people about the factors which can cause malaria.”

Adding further, Nikhil Chatterjee, VP – Marketing, PCI said “Today, malaria has become a global problem resulting to over one million deaths each year. Malaria exacts a serious toll of illness and death amongst pregnant women and children who are largely affected with the problem. As specialists in the field of pest management and in business for more than half a century, we know that only an integrated approach can

effectively tackle the mosquito menace. An integral aspect of all operations is the initiative and co-operation of local residents through awareness programs. We aim to control the mosquito menace through operations to be undertaken in small industrial towns, townships, housing colonies, villages and major cities in different parts of the country. Through our mission we yearn to reduce malaria transmission, provide adequate relief to the affected population, prevent further spread of the epidemic and develop sustainable malaria research capacity through partnerships with experts from various fields.”

About Metropolis Heath ServicesMetropolis Health Services (I) Ltd. was founded by Dr. Sushil Shah in 1981. Metropolis has 50 state-of-the-art laboratories in India and is India’s first corporate diagnostic centers chain with global presence like Sri Lanka, UAE, South Africa, USA and Thailand. Metropolis provides over 3600 specialized tests under a single roof ranging from oncology to genetics, molecular biology and immunoassays using best-of-breed and latest diagnostic equipment. Metropolis is a preferred referral center for more than 20,000 laboratories, clinicians, hospitals and research institutions across the nation. The CAP, CLIA (USA), NABL accredited and ISO 9002 certified Metropolis chain of laboratories has over 350 franchisees and is a preferred partner for providing quality testing to over 10,000-referral network across the country. Services include Clinical Laboratory Medicine, Radiology & Imaging Services, Hospital Laboratory Management, Central Laboratory Services for Clinical Trials, Site Management Services, Home Health Services, Preventive Health Check-ups and Remote Pathology Testing Services.

About PCIPCI is the leading pest management company that has pioneered the concept of pest management, related to a cross-sector of establishments in India. Established in 1954, PCI is headed by Mr. Anil S. Rao, son of visionary entrepreneur, N. S. Rao, who has been the driving force behind research-oriented solutions in the arena of pest management. The prime objective of PCI is to remain the standard bearer in the industry in terms of ethics and technical competence and provide high quality and cost-effective solutions that would befit changing customer demands. With 54 years of experience, PCI has graduated from a simple pest control company to a comprehensive pest management solutions provider. The products list is equally innovative and environment-friendly, with PCI products being sold under illustrious brands and attractive packaging by many companies both within India and Asia. PCI is India’s first and largest professional pest management enterprise and is responsible for constructing an industry and not just a company. Setting national standards to penning down of directives at associations has been a part of PCI’s regular contribution to a Rs. 800 crores industry.

IpcaContact

20

Ipca’s Clinical Study accepted for Poster Symposia PresentationA clinical study entitled 'Evaluation of efficacy and safety of cefotaxime sodium and sulbactam in children with lower respiratory tract infections', conducted by Medical Affairs and Clinical Research Department of Ipca Laboratories Ltd. has been accepted for Poster Symposia Presentation at the forthcoming 2nd Congress of the European Academy of Paediatrics – EAP 2008, to be held in Nice, France.

This poster is also one of the few selected posters, which has been accepted for oral presentation at the Congress.

This prestigious Paediatric Congress is organized by three

foremost European paediatric subspecialty societies: ESPNIC, ESPR and EAP.

EAP 2008 NICE expects over 3000 experts in all fields of paediatrics and will provide an unparalleled opportunity for networking with the leading experts in the field of paediatrics and neonatal care.

The proceedings of the Congress will be published in the on-line journal supplement of the Archives of Diseases in Childhood [BMJ (British Medical Journal) Publications].

The third NCE (New Chemical Entity) is being developed in joint collaboration with IICT (Hyderabad). This NCE has shown much promise in the treatment of intestinal ulcer. The most striking feature of this molecule is its potential to cure different kinds of ulcers which none of the existing drugs is capable of.

One of the earlier two NCEs being developed in collaboration with CDRI (Central Drug Research Institute, Lucknow) as a novel anti-malarial has crossed the initial hurdles. It would be entering Phase-I clinical trials very soon. The second

New Chemical Entity at Ipca Soon

News

Ipca’s Major Step towards Patient Safety

Drug safety is an important consideration for all stakeholders involved with drugs, which includes health care professionals, who are prescribers of the product; patients, who consume the drug; drug regulatory authorities and pharmaceutical companies who are involved in manufacturing and marketing drugs.

All medicines have potential risks as well as benefits. They are prescribed only when the beneficial effects override consideration of any adverse events, which may result from its use. In order to prevent or reduce harm to patients and thus improve public health, mechanisms for evaluating and monitoring the safety of medicines in clinical use are vital.

Patient safety is the fundamental principle for Ipca. Ipca is committed towards rational and safe use of medicines and has therefore taken the initiative of setting up a Corporate Pharmacovigilance Cell.

Pharmacovigilance refers to the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. The aim of pharmacovigilance is to protect public health by identifying,

evaluating and minimizing safety issues to ensure that the overall benefits of medicines outweigh the risks.

It is with this aim that a Corporate Pharmacovigilance Cell has been set up at Ipca’s Head Office. The Cell will function under the Medical Affairs and Clinical Research Department. Ms. Geeta S. Naik will head it with supervision by Dr. Anil Pareek, Sr. Vice President – Medical Affairs and Clinical Research. Ms. Nilam Jhanwar – Sr. Officer, Pharmacovigilance will assist Ms. Naik in the day-to-day functioning of the Cell.

The Cell will monitor adverse events from both the domestic as well as the international markets. It will create awareness of pharmacovigilance among the field force and marketing team. It will collate adverse events from clinicians, evaluate them, take corrective actions and inform the practitioners on the effective use of the drug. The Cell will also maintain a global safety database for Ipca’s products.

Setting up of the Corporate Pharmacovigilance Cell is a major step taken by Ipca to ensure the safe use of drugs, and to protect public health.

one is getting ready for the 2nd INDA (Investigational New Drug Application) filing.

These developments are the result of the initiative taken by Ipca to join the elite group of Indian Pharma companies having New Drug Discovery/Development programs in their arsenal to fight human suffering.

Ipca Contact

21

Good SamaritansWe had an overwhelming response to the blood donation camp held on June 20, ‘08 at the HO, Mumbai. Organized with the help of the B.Y.L. Nair Hospital Blood Bank, Mumbai Central, the day-long camp had more than 200 people visiting it and over 158 bottles of blood collected.Our Managing Director, Mr. Premchand Godha, visited the camp and was very happy to see the enthusiasm of the people. Employees were also deeply inspired to donate blood when they saw the active participation from the senior management team.

Each donor received:1. A certificate from the State Blood Preservation Council, Maharashtra State2. A donor card 3. A blood donation badgeNot only this, the donors will get one bottle of blood for self, relatives or friends (Valid for two years).We sincerely thank all Ipcaites for their whole-hearted support and active participation in this noble cause.

– Ashok Sharma

Mr. Abhijeet Kale, the first donor, receiving a certificate from Mr. Godha. Mrs. Prabhu from the Nair blood bank and Mr. Ashok Sharma from Corporate-HR were also present.

The enthusiastic Corporate-HR Team

Our MD, Mr. Premchand Godha, spending a few moments with the donors

Blood donation in progress

A New Gym for Employees (Athal & Piparia)

“Do your workout regularly; your work will not get you out”. This is the thought which has prompted Mr. V. S. S. Kushwaha to set up a gymnasium for the staff at Athal and Piparia plants.

The gymnasium was inaugurated on June 5, ‘08 by Mr. Kushwaha in the presence of a huge crowd of employees from Athal and Piparia.

The gymnasium, situated at the guest house of the company, has a treadmill, four multi-gym stations, dumb-bells and pilates. The gym is open to all employees as well as the guests who stay at the guest house, in the morning from 6 to 9 and from 5 to 8 in the evening.

– N. B. Sinha

CSR

Mr. V. S. S. Kushwaha with his team

IpcaContact22

Keeping in line with this motto, we, in collaboration with Achiever’s Academy, organized ‘English Language Development’ classes for our employees’ children.

The first batch of 45 days was completed on June 15, ‘08. At the end of the first batch, we conducted a Career Counseling cum Personality Development Workshop.

Mr. P. P. Dubey, DGM – HR and Admin in his speech, guided children on how to choose a career of their own interest. His thoughts proved to be enlightening to the children.

Moulding Young Minds (Ratlam)

Our corporate trainer, Mr. D. P. Anjne’s speech on career guidance was quite informative. He directed them on how to pursue a better career. Mr. Narendra Sharma guided them on goal setting while Mr. Pankaj Mittal introduced Jaycee activities to the children while explaining about the Junior Jaycee Club.

We thank Mr. Rajendra Kumawat for making all the arrangements for the program.

'Welfare of employees is our habit. We are always on our toes where the employees’ welfare is concerned.'

Future generation listening keenly to what the future holds

Food for thought by Mr. P. P. Dubey

CSR

Today, several people die of cancer due to chewing tobacco. There is an increasing need to spread awareness about the ill effects of tobacco. Ipca Piparia makes a

positive attempt to contribute to this noble initiative.

Say No to Tobacco

May 31 is celebrated as World NO Tobacco Day. We, at Ipca Piparia, participated in the celebrations by arranging a lecture on tobacco awareness. Dr. Pradip Patel, MD, Medical Officer, Cottage Hospital, Silvassa made a presentation on the topic which was followed by a slide show on the menaces of tobacco.

All employees actively participated in the program and took an oath to say NO to Tobacco!

Employees taking an oath on World NO Tobacco Day at Piparia

Ipca Contact

23

Þeer. He´keÀeMe MeveJeejs, He´smeer[svì - ceeveJe mebmeeOeve efJeYeeie kesÀ ceeie&oMe&ve SJeb FHkeÀe ceekexÀefìbie keÀer 3meer ìerce kesÀ cewvespej, Þeer. jepeerJe ceesnve SJeb GvekeÀer ìerce kesÀ He´³eemeeW mes FHkeÀe Fvoewj ceW DeHew´ue 6, 08 keÀes cesef[keÀue kesÀcHe Dee³eesefpele efkeÀ³ee ie³ee efpemeceW Fvoewj kesÀ leerve Jeefj<þ [e@. S. kesÀ. Heb®eesefue³ee - keÀeef[&³eeuee@efpemì, [e@. efveefleve meent - keÀvmeueefìbie efHeÀefpeefMe³eve [e³eyeerìerpe (ceOegcesn) SJeb [e@. DeeMeer<e Heìsue, Deefmemìbì He´esHesÀmej, Sce.peer.Sce. cesef[keÀue keÀe@uespe, Fvoewj GHeefmLele ngS~

keÀe³e&ke´Àce kesÀ MegYeejbYe ceW FHkeÀe, Fvoewj kesÀ Þeer. DeeueeskeÀ oJes ves meYeer [e@keÌìme& keÀe

cesef[keÀue kesÀcHe (Fvoewj)

mJeeiele keÀj GvekeÀe Heefj®e³e efo³ee SJeb Þeer. meer. Sme. efnueeue, Þeer. Sme. kesÀ. keÀveesefpe³ee SJeb Þeer. ceveer<e efMeletle ves [e@keÌìme& keÀe HetÀueeW mes mJeeiele efkeÀ³ee~

[e@. DeeMeer<e Heìsue ves ueieYeie 30 keÀce&®eeefj³eeW SJeb ÞeefcekeÀeW keÀe cesef[keÀue efHeÀpeerkeÀue ®eskeÀDeHe keÀj cesef[efmeve He´smke´ÀeF&y[ keÀer SJeb mJemLe jnves kesÀ efJeefYeVe GHe®eej yelee³es~ [e@. S. kesÀ. Heb®eesefue³ee SJeb [e@. efveefleve meent ves keÀeGbmeefuebie keÀj Jele&ceeve Heefj¢M³e ceW yeæ{leer efyeceeefj³eeW Ëo³eIeele (neì& DeìwkeÀ) keÀer jeskeÀLeece SJeb peerJeveMewueer ceW HeefjJele&ve Yeejleer³e HeefjJesMe ceW SJeb [e³eyeerìerpe SJeb kesÀueesmì^eue keÀer jeskeÀLeece kesÀ yeejs ces peevekeÀejer oer~

³en cesef[keÀue kesÀcHe FHkeÀe Fvoewj kesÀ Þeer. DeeueeskeÀ oJes, ceveer<e efMeletle, Deej. ef[kegÀvee, jengue cesnlee, DeeMeer<e De$es SJeb kewÀueeMe Keg[erJeeue SJeb ceekexÀefìbie 3 meer ìerce kesÀ Þeer. jepeerJe ceesnve, Go³e Deie´Jeeue SJeb meeefLe³eesb kesÀ men³eesie mes mecHeVe ngDee~ keÀe³e&ke´Àce kesÀ Deble ceW Þeer. DeeueeskeÀ oJes ves [e@keÌìme& keÀe DeeYeej ceeveles ngS GvnW FHkeÀe Fvoewj kesÀ keÀce&®eeefj³eeW SJeb ÞeefcekeÀeW keÀer Deesj mes DeeMJemle efkeÀ³ee efkeÀ GvnesveW pees Yeer ceeie&oMe&ve He´eHle efkeÀ³ee nw Gmes Jes DeHeves owefvekeÀ peerJeve ceW DeHevee³eWies~

- DeeMeer<e De$es

Jele&ceeve peerJeveMewueer ceW efvele efove nes jns yeoueeJe kesÀ keÀejCe J³eefkeÌle ceeveefmekeÀ Deewj

MeejerefjkeÀ oesveeW ªHe mes DeHeves DeeHe keÀes yengle leveeJeMeerue cenmetme keÀj jne nw, efpemekeÀe

Demej GmekesÀ HeeefjJeeefjkeÀ, meeceeefpekeÀ peerJeve Deewj veewkeÀjer Hej Yeer Heæ[ jne nw~ Fmeer

keÀes O³eeve ceW jKeles ngS FHkeÀe-Fvoewj kesÀ Þeer DeeueeskeÀ oJes kesÀ He´³eemeeW mes efoveebkeÀ 14

mes 28 DeHe´wue 08 lekeÀ ³eesiee efMeefyej ueiee³ee ie³ee efpemeceW ³eesie iegª Þeer. osMeHeeb[s peer

(efjìe³e[& yeQkeÀ DeeefHeÀmej) ves keÀejKeevee He´yebOekeÀ Þeer. Jner. kesÀ. HejebpeHes meefnle ueieYeie

20 keÀce&®eeefj³eeW keÀes He´efMe#eCe efo³ee~

Þeer. osMeHeeb[s ves 15 efove kesÀ He´efMe#eCe me$e ceW efJeefYeVe ³eesie pewmes - met³e& vecemkeÀej,

³eesie efveêe, He´eCee³eece, Jeke´Àemeve, DeOo&-HetCe& efleleueer, MeJeemeve, cekeÀjemeve,

He¨eemeve, efme×emeve, Yegpebieemeve, ®eke´Àemeve, HeJe&leemeve, ces[erìsMeve SJeb DeemeveeW keÀe

He´efMe#eCe efo³ee~

³eesie efMeefyej kesÀ Deefvlece efove Þeer. Jner. kesÀ. HejebpeHes, Þeer. Sme. kesÀ. keÀveesefpe³ee,

Þeer. ceveer<e efMelegle SJeb Þeer. DeeueeskeÀ oJes ves Þeer. osMeHeeb[speer keÀe mecceeve keÀjles ngS

GvekeÀe DeeYeej ceevee~

- DeeMeer<e De$es

Fvoewj ceW ³eesiee He´efMe#eCe efMeefyej

CSR

IpcaContact24

TQMA Great Learning Experience

This time around, in our series of continuous learning and

growth, Ipca team consisting of eight people from different

plant locations visited M/s Sona Koyo Steering Systems Ltd.,

Gurgaon- Haryana on May 22, ‘08.

Sona Koyo Steering Systems Limited (SKSSL) is a technical

and financial joint venture company of Koyo Seiko Company,

Japan, and the global technology leader in Steering Systems.

The company received the Deming Award – the world’s most

coveted honor for excellence in Total Quality Management

since November ‘03, and is surging ahead in its journey

of TQM.

Customer satisfaction continues to be of utmost importance to

Sona Koyo Steering Systems, as do consistent quality, constant

innovation, value engineering, process improvement and

customer orientation.

Our Experience Good practices observed

• Helping supplier to implement TQM in order to get good

quality product from supplier

• X– Matrix: Integration of KRA (MBR) into KGA (Group

Kaizen Activities)

• The good Thought for the Day displayed on board

Environment

• Use of 500ml waste bottles instead of 1000ml to

save cost

• Zero discharge ETP facility (No water discharged outside)

Sona CSR council

• Tie-up with local ITI institutes for easy availability of new

and fresh skills

• 4-bed hospital in village AS CSR

• Various CSR activities in village through employees’

spouses

• Conducting various competitions for kids: Drawing,

sports, etc.

• Involved Trade union in CSR activities

• Internal magazine SONA PARIVAR published in both

Hindi and English

• Conducting training programs for spouses/couples

• Received CSR Appreciation Award from the Government

of India

Mr. Manoj Rana -TQM Coordinator, explaining the TQM system at Sona

The Sona Koyo Steering System experience was indeed an enlightening one. Here is a review of the visit.

Mr. Hari Nair, V.P-HR, introducing Sona to the Ipca team

Good HR practices

• 4-day induction program for new employees (middle

management and above)

• 18-day MDP (tie-up with local management institute)

• Employee Mentoring: joint session with mentor

and mentoree

• Very good model workshop training hall for practical

training on machines/process for new employees

• Knowledge-sharing forum

• Sona group HR mega conclaves for various other

companies from branding to bonding

• Initiatives for improving the most important resource, the

Human Resource, as well as plant equipment

Total Productive Maintenance (TPM) concept adopted to

Ipca Contact

25

On June 10, ‘08, a TQM Award function was organized at Ipca, Indore. Mr. V. K. Paranjape, General Manager – Operations, Mr. C. S. Hillal, TQM Champion and Chief Coordinator, Mr. S. K. Kanojia, TQM Champion and all HODs of the plant were present for the function.

Gift vouchers for the period of October ‘07 to March ‘08 were distributed to more than 170 employees of Indore and other location employees for their participation in the TQM journey.

TQM Awards & Accolades (Indore)

Mr. Ashish Atre welcomed all the invitees and briefed them on the workers’ and employees' involvement in the TQM journey during the last six months. Mr. Paranjape appreciated all the employees for their contribution. He also said that every individual must take initiative to complete the TQM project.

Mr. Hillal, in his speech, expressed his happiness to see an increased involvement of workers as compared to the previous years.

Mr. S. K. Kanojia, Mr. Manish Shitut, Mr. R. K. Surana, Mr. Alok Dave, Mr. R. K. Jain and Mr. B. K. Saktawat also addressed the employees and motivated them for a continued participation.

– Ashish Atre

Total Quality Management (TQM) has been in the industry for quite some time now. Ipca too participates in this improvement drive through huge employee participation. Find out more...

Ipca team along with M/s. Sona – HR team(From L-R): Mr. Manoj Negi (Sona), Mr. Rajnish Saini (Sona),

Mr. D. P. Anjne, Mr. C. S. Soni, Mr. Nandji Singh, Mr. Manohar Kuwar, Mr. R. N. Attarde, Mr. Ashok Sharma, Mr. K. K. Ajmera, Mr. Aditya

Sinha (Sona), Mr. M. Rehman and Mr. Trinayan Saikia (Sona)

improve performance through the philosophy of

prevention. SKSSL aims to achieve zero accidents,

zero defects and zero breakdowns by using the Koyo

Production System as the foundation of all change

programs.

We would like to thank Sona for the great

effort, concern and care shown during our team visit

to the plant. Above all, we sincerely appreciate the

unforgettable hospitality extended to us.

– Ashok Sharma

TQM

TQM Awards ceremony in progress

IpcaContact

Depression: the Silent KillerPhysical and mental health are the two important components of a human body. The awareness of mental

health and its disorders are increasing by the day. Simultaneously, the social stigma about psychiatric illness is also reducing. People are opting to visit psychiatrists and psychologists for their stress related complaints. Considering the importance of mental health, WHO (World Health Organization) also dedicated the first year of

the millennium, 2001 as the ‘Year of Mental Health’.

What is depression? Depression is a mood disorder characterized by persistent low mood which results in abnormalities of speech, thought, body functions and behavior. Depression can be the result of a traumatic experience, such as the sudden loss of a loved one, a divorce or even a loss of job. Most of us are able to cope with such stressful events. Over a period of time, a majority of us are able to return to our normal activities. But when these feelings of sadness and other symptoms make it hard for one to get through the day, and when the symptoms last for more than a couple of weeks, then it is called clinical depression.Clinical depression is not just grief or sadness. It is an illness that can challenge one’s ability to perform even routine daily activities. At its worst, depression may lead the victim to contemplate or commit suicide.Depression factsAbout 5-10% of women and 2-5% of men experience at least one major depressive episode during their adult life. Depression affects people of all races, incomes and ages, but it is three to five times more common in the elderly population than in young people.Depression represents a burden for both patient and their family. There is increased risk of cardiovascular, cerebrovascular disorder and accidents. Suicidal thoughts and attempts lead to increased mortality in a depressive patient.Causes of depressionThe causes of depression are complex. Genetic, biological and environmental factors can contribute to its development.1. Genetic: Certain types of depression seem to run in certain families. Research is ongoing as to exactly which genes are involved in depression.

2. Biochemical: Currently, it appears that there is a biochemical cause for depression, occurring as a result of abnormalities in the levels of certain chemicals in the brain. These chemicals are called neurotransmitters. Low level of neurotransmitters like serotonin, noradrenaline may be responsible for depressive illness.3. Environmental conditions: Difficult life events, loss, change, or persistent stress can cause levels of neurotransmitters to become unbalanced, leading to depression, e.g., unemployment, low socio-economic status, marital problems, divorce of parents, etc.4. Stressful events: Sudden events like accidents, loss of job, failure in examination, failure in love affair, death of father or mother, etc., also can lead to depression. 5. Medical illness leading to depression: Depression is more likely to occur with certain medical conditions. These ‘co-occurring’ conditions include heart disease, stroke, cancer, AIDs, Parkinson’s disease, Alzheimer’s disease, etc.

Symptoms of depression

Physical symptoms

Emotional symptoms

Feelings of hopelessness, worthlessness, helplessness Feelings of guilt Crying spells

Other symptoms

Negative thinking Minimal interaction with other people Suicidal thoughts and/or attempts

Insomnia (lack of sleep) Loss of appetite / increased appetite Weight loss / weight gain Low energy levels Loss of interest or pleasure in usual activities Tiredness Chronic pain like headache, backache, etc.

26

Medical

Ipca Contact

Children with depression also experience these classic symptoms, but may exhibit other symptoms as well, including the following:

Poor school performance

Persistent boredom

Frequent complaints of physical problems such as headaches and stomach aches

Parents of children with depression report noticing the following behavioral changes.

The child spends more time alone, away from friends and family.

The child actually becomes more ‘clingy’ and may become more dependent on certain relationships.

The child expresses thoughts about hurting him or herself, or exhibits harmful behavior.

The child seems to be overly pessimistic or exhibits excessive guilt or worthlessness.

In elderly patients, certain other symptoms also may be noted like diminished ability to think or concentrate, memory impairment, etc. Patients having severe depression may require admission into the hospital till the reduction of intensity of their illness.

Diagnosis and management of depression

Various rating scales are used for diagnosing and rating psychiatric illness. Generally these tests are done by psychologists:

HAM-D- Hamilton Depression Rating Scale

MADRS- Montgomery Åsberg Depression Rating Scale

CGI – Clinical Global Impression Scale

IQ test – Intelligent Quotient test

Role of psychotherapy

Psychotherapy involves working with a psychotherapist to figure out ways to solve problems and cope with depression. Psychotherapy involves multiple aspects like psychoanalysis, behavioral therapy, supportive counseling, interpersonal therapy, etc. It involves multiple interactive sessions spread over weeks to months.

Psychoanalysis: This is the traditional psychological approach to depression and involves intensive analysis of the emotional aspects and attitudes.

Supportive counseling: It includes reassurance, guidance, explanation, encouragement, support and the opportunity to express emotions.

Interpersonal therapy: This helps to alleviate depressive symptoms and helps the patient

Molecule Brand name

Paroxetine PariSertraline InosertEscitalopram Recita Escitalopram + Clonazepam Recita forteDuloxetine Sympta Amitryptiline + EmotripChlordiazepoxide

to develop more effective skills for coping with social and interpersonal relationships.

Cognitive therapy: It aims to change negative thought patterns that are believed to contribute to depression and other problems.

Behavioral therapy: It is very useful in counteracting the lack of energy that often accompanies depression, helping involvement in more constructive activity.

Role of drug therapy: Antidepressants

There are various classes of drugs available for the management of depression. The primary aim of their use is to reduce symptoms, improving social interaction, improvement of daily activities and over all improvement of quality of life.

Tricyclic antidepressants: Amitryptyline, Imipramine, Nortryptyline, Dothiepin

Selective serotonin reuptake inhibitors (SSRIs): Fluoxetine, Sertraline, Fluvoxamine, Paroxetine, Citalopram, Escitalopram

Serotonin norepinephrine reuptake inhibitors (SNRIs): Venlafaxine, Duloxetine

NASSA (Noradrenergic and specific serotonergic antidepressants): Mirtazapine

NaRI ( Norepinephrine reuptake inhibitors): Reboxetine First three categories of drugs are popular among the psychiatrists, physicians or family physicians.

Self-Care at homeTry to identify and focus on activities that make one feel better.

It is important to do things for oneself and try to maintain a positive outlook.

Talk with friends, family members and consider joining a support group. Communicating and discussing one’s feelings is an integral part of treatment.

Regular exercise and proper diet are essential to good health.

Try to get enough rest and maintain a regular sleeping pattern.

Avoid drinking alcohol or using any illicit substances.

27Medical Team

Medical

Ipca markets the following drugs for the treatment of depression

IpcaContact28

WorldWorld Environment Day is an occasion to seek solutions to different issues plaguing

our environment. We, the Ipcaites, left no stone unturned to celebrate this day at all our sites.

efJeMJe He³ee&JejCe efoJeme efoveebkeÀ 05 petve 08 keÀes FHkeÀe - Fvoewj ceW n<eexuueeme HetJe&keÀ cevee³ee ie³ee~ Fme DeJemej Hej keÀejKeevee Heefjmej mes ueieer peceerve Hej Je=#eejesHeCe keÀe³e&¬eÀce jKee ie³ee efpemeceW cegK³e DeefleefLe HetJe& Hee<e&o Þeer. jepesvê MegkeÌuee Les~ keÀejKeevee ÒeyebOe Þeer. Jner. kesÀ. HejebpeHes ves Je=#eejesHeCe keÀj meYeer keÀce&®eeefj³eeW SJeb ÞeefcekeÀeW keÀes ceeveJe peerJeve ceW He³ee&JejCe keÀer cenÊee yeleeles ngS meYeer mes DeefOekeÀ mes DeefOekeÀ cee$ee ceW Je=#eejesHeCe keÀjves keÀe DevegjesOe efkeÀ³ee~ keÀe³e&¬eÀce ceW He³ee&JejCe keÀer ieCe Þeer. Sme. kesÀ. keÀveesefpe³ee, Þeer. ceveer<e efMeletle, Þeer. DeeueeskeÀ oJes, Þeer. yeer. kesÀ. MekeÌleeJele, Þeer. levce³e oeref#ele, Þeer. ceveespe meesvemeues, Þeer. HebkeÀpe Mecee&, Þeer. efJejsvê þekegÀj meefnle Dev³e keÀce&®eeefj³eeW SJeb ÞeefcekeÀeW ves ueieYeie 25 Je=#e ueiee³es~

FHkeÀe Fvoewj ceW peien keÀer keÀceer nesves kesÀ yeeJepeto kebÀHeveer kesÀ Jeefjÿ DeefOekeÀeefj³eeW kesÀ ceeie&oMe&ve ceW Þeer. levce³e oeref#ele - He³ee&JejCe SJeb megj#ee DeefOekeÀejer kesÀ DevegkeÀjCeer³e HenueeW mes keÀejKeeves mes ueieer ueieYeie 2400 Jeie& ceerìj Yetefce Hej leerve GÐeeveeW keÀe

n<eexuueeme - efJeMJe He³ee&JejCe efoJeme keÀe

Go Green

Fvoewj

FHkeÀe jleueece Hueebì ceW petve 5, 08 keÀes efJeMJe He³ee&JejCe efoJeme yeæ[ss Glmeen mes cevee³ee ie³ee~ Fme DeJemej Hej keÀejKeevee Heefjmej ceW HeewOeejesHeCe keÀe³e&ke´Àce efkeÀ³ee ie³ee Je He³ee&JejCe kesÀ He´efle peeie©keÀlee oMee&les ngS keÀe³e&ke´Àce ceW meYeer efJeYeeie SJeb meYeer mlej kesÀ keÀce&®eeefj³eeW ves Yeeie efue³ee ~

He³ee&JejCe mJemLe lees ceeveJe mJemLe !jleueece

Fme DeJemej Hej JeeFme He´sefme[Wì Þeer. peer. Jeer. Deej. veeiesMe ves He³ee&JejCe kesÀ cenÊJe Hej He´keÀeMe [eueles ngS yelee³ee efkeÀ He³ee&JejCe keÀes meeHeÀ SJeb mJe®í jKevee He´l³eskeÀ veeieefjkeÀ keÀer efpeccesoejer nw Je He³ee&JejCe, mJeemLe SJeb megj#ee efJeYeeie kesÀ cewvespej Þeer. megyeesOe kegÀceej ves keÀce&®eeefj³eeW mes DeHeves Üeje ueiee³es ie³es HeewOeesb kesÀ mebj#eCe keÀer efpeccesoejer mes DeJeiele keÀje³ee SJeb He³ee&JejCe kesÀ He´efle meYeer keÀer efpeccesoejer mes Yeer DeJeiele keÀje³ee ~

GHeefmLele keÀce&®eeefj³eeW ves kebÀHeveer Heefjmej ceW HeewOeejesHeCe efkeÀ³ee Je He³ee&JejCe meeefnl³e keÀe efJecees®eve efkeÀ³ee ~ Fme DeJemej Hej [er. Heer. Devpeves, Deej. Heer. Mecee&, Sme. kesÀ. Mecee&, efJeke´Àce keÀesþejer, [e@. ceveer<e iegHlee, S®e. Sme. HeJeej, ieesJeOe&ve ieæ{Jeeue, Fvêmesve efmebn, efHe³eg<ejepe, DeeMeerle efo#eerle, melleej Deueer, Jemeerce cevmetjer, veeruece HeC[³ee, Þeerceleer HeuueJeer mejceb[ue efoiecyej, DeJeveerMe efmebn, cegvveeueeue ³eeoJe, ³eesiesvêefmebn Deeefo yeæ[err mebK³ee cessb ceewpego Les ~ Deble ceW keÀe³e&ke´Àce keÀe DeeYeej vejsvê Mecee& ves ceevee ~

efvecee&Ce keÀjJeekeÀj Gve Hej Je=#e jesefHele efkeÀ³es leLee Fve Je=#eeW keÀer eEme®eeF& kesÀ efueS keÀejKeeves ceW GHe³eesie efkeÀ³es ie³es Heeveer keÀes ner Hegve: mJe®í keÀjkesÀ efmeb®eeF& keÀer peeleer nw~ Fme keÀe³e& ceW GvekesÀ DeefOevemLe meeLeer Þeer. yeblee ³eeoJe keÀe Yeer mejenveer³e ³eesieoeve jne~ FHkeÀe-Fvoewj kesÀ keÀce&®eeefj³eeW SJeb ÞeefcekeÀeW kesÀ GHejskeÌle meecetefnkeÀ Òe³eeme ves Fve HebeqkeÌle³eeW keÀes ®eefjleeLe& efkeÀ³ee nw~

"cebefpeue Gvnsb ner efceueleer nw efpevekesÀ meHeveeW ceW peeve nesleer nw

HebKees mes kegÀí veneR neslee newsueeW mes Gæ[eve nesleer nw"

keÀe³e&¬eÀce kesÀ Deble ceW Þeer. levce³e oeref#ele ves meYeer keÀe DeeYeej ceevee SJeb YeefJe<³e ceW He³ee&JejCe megOeej kesÀ efueS þesme keÀoce Gþeves nsleg men³eesie Òeoeve keÀjves keÀer DeHeerue keÀer~

Fvoewj

Þeer. Jner. kesÀ. HejebpeHes, Þeer. DeeueeskeÀ oJes,

Þeer. Sme. kesÀ. keÀveesefpe³ee Je=#eejesHeCe keÀjles ngS

29

Ipca Contact

Cherishing moments of World Environment Day

efoveebkeÀ petve 5, 08 keÀes F&HkeÀe - efHeHeefj³ee ceW efJeée He³ee&JejCe efoJeme Hetjs Gcebie SJeb mebkeÀuHe mes cevee³ee ie³ee~ Fme DeJemej Hej meYeer keÀce&®eeefj³eeW ves He³ee&JejCe kesÀ He´efle DeHeveer He´efleye×lee SJeb mebkeÀuHe keÀes ognje³ee~

He´l³eskeÀ Je<e& keÀer Yeebefle Fme Hegveerle DeJemej Hej Je=#eejesHeCe keÀe Dee³eespeve efkeÀ³ee ie³ee, efpemeceW Jeefj<þ ceneHe´yebOekeÀ Þeer. efJe<CegMejCe efmebn kegÀMeJeenepeer ves DeHevee Deveceesue

mece³e efvekeÀeue keÀj Je=#eejesHeCe efkeÀ³ee~ Dev³e He´yebOekeÀeW leLee keÀce&®eeefj³eeW ves Yeer meËo³e Je=#eejesHeCe keÀj Hegveerle keÀe³e&ceW menYeeieer yeveW~ Je=#eejesHeCe keÀe Dee³eespeve HewÀkeÌì^er mes mejs meæ[keÀ kesÀ efkeÀveejs efkeÀ³ee ie³ee~

efJeée He³ee&JejCe efoJeme mebHeVe

ef®e$e ceW meYeer ÒeyebOekeÀ leLee keÀce&®eejer Je=#eejesHeCe kesÀ mece³e Hej GHeefmLele

keÀce&®eejer³eeW Üeje Je=#eejesHeCe keÀe Dee³eespeve

efmeueJeemee

Towards a Green CauseAthal

In keeping with Ipca’s commitment towards environment protection, the World Environment Day was celebrated with great zeal on June 5, 2008 at Athal.The day witnessed a number of events such as plantation of about 50 saplings of Ashoka by employees at all levels and a seminar on ‘Health Hazards of Chewing Tobacco & items of Tobacco’ by our medical officer Dr. Pradip Patel. Dr. Patel stressed on the fact that the habit of chewing tobacco causes many health related problems. It leads to cancer and a slow and painful death. He also spoke about the health hazards related to alcohol and smoking. During the seminar, Mr. S.

S. Jagannath, Manager – EHS and Mr. Kaushik Mahyavanshi, Jr. Officer – EHS, briefed the employees on the past and ongoing activities related to Health and Environment.

– Sanat Desai

Mahad

Exon team celebrated World Environment Day on June 5, ‘08 in the presence of Field officer, Mr. Rahul Mote, M. P. C. B (Mahad).

Mr. Anil Mehra, Mr. P. P. Vadake, Mr. S. B. Shelke, Mr. M. Rehman and Exon team planted saplings in the company premises. During the celebrations, all present took the oath to keep the environment neat and clean.

Environment Day

Exon team celebrating the World Environment Day

Visit to GermanyUnder the leadership of Mr. P. B. Nair, VP – Manufacturing and Mr. V. S. S. Kushwaha, Sr. GM – Operations, two staff members of Athal, Mr. Manohar Kuwar and Mr. Jaydevsinh Thakor, visited Germany for getting trained on the latest Compression Machine of FETTE. The visit was planned between April 21 and 24, ‘08.

Mr. Kuwar and Mr. Thakor, both joined Ipca as workmen in the late 90s. They have continuously set high standards of performance since then. Recognizing their potential, the management promoted them to Staff cadre in June 2007. Both are very actively involved in the TQM journey of Ipca. Mr. Manohar has represented Athal in the recently held INSSAN summit to present his project.

Sharing their experience of the Germany visit, Mr. Kuwar and Mr. Thakor said, “We are thankful to the management for giving us this opportunity. It was like a once-in-a-lifetime opportunity and we were very excited about it. As this was our first trip outside India, we were a bit nervous but the people were so helpful that our visit went on hassle free.” They are also excited about the machine and gave brief details of the machine.

The compression machine has a very high output capacity of 100 RPM compared to the currently installed machines with an average output capacity of 50 RPM. Thus the new machine is expected to give double output than the current machines. The machine is currently under installation.

– D. P. Singh

30

IpcaContact

Athal

Children of Athal employees displayed their creativity in a drawing and coloring competition organized by Ipca. Around 34 children of different age groups participated in this. Apart from the first three winners, consolation prizes were also given out to every participant.

Colors and Crayons

Quiz CompetitionThe inter-departmental Quiz Competition at Athal had 12 teams from various departments. The team from QA – Stability emerged winners.

(From L-R): Mr. P. B. Nair, Mr. Manohar Kuwar, Mr. V. S. S. Kushwaha and Mr. Jaydevsinh Thakor

Mr. D. P. Singh trying out his creativity with kids

– D. P. Singh

All parents and children at the end of the Drawing Competition

Kaun Banega Brain MasterLike any reality game show, we also had a Brain Master Quiz Contest for our employees at Piparia.

Knowledge is power. It removes darkness and brings confidence. Most of all, knowledge is the almighty. To bring out this Gyan as fun at work, Ipca Piparia, organized the much awaited Brain Master Quiz contest 2008 on June 3, ‘08 at the training hall.

Senior General Manager – Operations, Mr. V. S. S. Kushwaha, inaugurated the event which was hosted superbly by Mr. Chandrakant Shrivastwa, Sr. teacher at Lions School, Silvassa.

In all there were five teams (two from Production, one from QC, one from QA and one from other departments). The QA team (represented by Mr. Sohil Khoja and Mr. Manoj Parmar) was declared the winner, while the QC team (represented by Mr. Bhaumik Patel and Ms. Shivani Gupta) clinched the title of runners-up. Mr. R. B. Panchal, QA Manager, distributed the prizes.

The training hall was packed to capacity and it looked like a studio set of a reality show like KBC. The whole show was a unique combination of fun, knowledge and work.

– N. B. Sinha

meeefnl³e mebie´n - SkeÀ DeveesKee Òe³eeme

Exon team has successfully prepared a two-day SGA workshop – English manual in the local language, i.e., Marathi. The program was inaugurated by Mr. K. K. Mandwaria, Mr. Mohd. Ismile and Mr. P. P. Vadake.

SGA Workshop – Now in MarathiThis program is helpful to upgrade plant activity, initiation from bottom line and presentation skills. We have also decided to cover all employees under the two-day SGA workshop during the current year.

The first program was conducted on May 5 and 6, ‘08 and was a great success. All the employees highly appreciated the program and expressed their view to conduct such trainings in future with everyone's involvement.

The two-day SGA Workshop Manual has been given to Makers Dombivali and Ipca Aurangabad to conduct such training programs at their respective locations.

– P. P. Vadake

Mahad

31

IpcaContact

Silvassa

Deepe kesÀ ³egie ceW ìer. Jner., kebÀcH³etìj Deeefo ves ceeveJe kesÀ mece³e keÀe HetCe& Deefleke´ÀceCe keÀj efue³ee nw~ Deepe ³es nceejer peerJeve keÀe SkeÀ DeefYeVe Debie nes ie³es nw~ HeÀueleë nce DeHeves meeefnl³e kesÀ Deveceesue jlveeW keÀes Yetueles pee jns nQ~ nce DeHeves yeewef×keÀ mees®e keÀe Nneme keÀj jns nw~

meeefnl³e kesÀ Oejesnj keÀer ³eeoeW keÀes mebpeesves kesÀ GÎsM³e mes Þeer. efJe. Sme. Sme. kegÀMeJeene peer kesÀ He´sjCee m$eesle mes Þeer. peieceesnve otyes, keÀleer³e DeefOekeÀejer - mìesme& kesÀ Üeje mJe. He´sce®ebo peer kesÀ keÀLee mebie´n leLee GHev³eemeeW keÀe DeveesKee mebie´n efkeÀ³ee pee jne nw~

Jele&ceeve ceW ceeve mejesJej, ieesoeve Deeefo Decej ke=Àefle³eeB Fve cesb Meeefceue nw~

Fme mebie´n keÀe ueeYe keÀce&®eejer ieCe yeæ[s Glmeen mes ues jns nw~ leLee DeHeves meeefnl³e keÀes mebpeesves ceW menYeeie keÀj jns nQ~

– lespeue Yeb[ejer

IpcaContact

32

Three Cheers to our AchieversThe Board Examination results are out and everyone’s hard work and determination have paid off.

So, it’s time for an applause!

Abhirav Ganesh Gholba, son of Mrs. Aarti G. Gholba has secured the MSCE 2008 (STD VII) Scholarship. He stood 62nd among 7.23 lakh students appearing for the exam in Maharashtra.

Maharashtra State Council of Examinations (MSCE) is an autonomous body established by School Education Department, Govt.

Budding Talent

of Maharashtra. The mission of the MSCE is to take up talent search at primary, secondary and professional levels, through reliable, transparent and valid conduction of examinations. About 66000 primary schools, 14000 secondary schools compete for the scholarship.

Abhirav studies in Std VIII at Swami Vivekanand International High School. He has indeed made his parents proud of his achievement.

We wish Abhirav all the best in his future endeavor!

Kanika Kapur, daughter of Lt. Col (Retd) Sanjay Kapur, GM (Operations), made the Ipca family proud by her stellar performance in the Xth CBSE Board result by securing 95.2%.

Her hard work and determination not only made her a consistent topper of Doon International School, Dehradun, but also the overall topper amongst girls in Dehradun. She also secured the 2nd position in Uttarakhand among girls.

Kanika is very creative and loves to draw and paint. She also enjoys music, dance and is an excellent swimmer. The aspiration of becoming a doctor is backed by both her father and mother. They are indeed proud parents today.

This is an encouragement and precedent to all the children of Ipca family to do well and make their parents proud. Keep up the good show!

Neeta S. Talreja, sister of Mr. Prakash Talreja (Asst Manager – QA, Kandla), stood first in the university in the M. Com examinations. We congratulate Neeta on her bright achievement and wish her success in all her future endeavors.

Karan Vohra, son of Sunil Vohra, has secured 96.4% in his Xth ICSE Board. He stood

second in his school, Saint Joseph’s Academy, Dehradun. Congratulations Karan on this

spectacular achievement!

Getting an MSCE scholarship is every student’s dream. And Abhirav has made his dream come true by passing the scholarship with brilliant performance.

Achievers’Corner

Ipca Contact

My wife called and said, “How long will you be with that newspaper? Will you come here and make your darling daughter eat her food?”

I tossed the paper away and rushed to the scene. My only daughter, Sindhu looked sad; tears were welling up in her eyes. In front of her, was a bowl filled to its brim with curd rice.

I cleared my throat, picked up the bowl and said, “Sindhu darling, why don’t you eat this? It looks delicious”. Sindhu softened a bit, “Ok dad, I will eat. But, promise me, if I eat the entire thing you will give me whatever I ask for.”

“Promise”, I covered the soft hand extended by her with mine, and clinched the deal. But I was anxious, “darling but please don’t ask dad to buy you anything very expensive. It is month end remember.”

“No dad. I don’t want anything expensive.” As she started eating, I was angry with myself for forcing the child something that she detested. After the ordeal was through, Sindhu came to me with her eyes wide with expectation, “Dad I want to have my head shaved off this Sunday!” “What?”, shrieked my wife, “You are a girl. Having your head shaved off is impossible.” My mother rasped, “She has been watching too much of television. Our culture is getting totally spoiled with these TV programs”.

“Sindhu darling, why don’t you ask for something else? We will be sad seeing you with a clean-shaven head”, I said. “Dad you promised to give me whatever I asked for. Now, you can’t go back on your words. That’s not fair”. She was almost in tears. Without hesitation,

I responded, “Ok a promise is a promise and it must be kept. Go ahead”.

“Are you out of your mind?” shouted my wife. “No. If we go back on our promise, she will never learn to honor her own. On Monday

morning, I dropped her at her school. It was a sight to watch her, head clean-shaven, walking towards her classroom. She turned around and waved. I waved back with a smile.

Just then, a boy alighted from a car and shouted, “Sindhuja please wait for me”. What struck me was the hairless head of that boy. Maybe that is the in-stuff, I thought. “Sir your daughter Sindhuja is amazing,” a woman interrupted my thoughts. Without bothering to introduce herself she continued, “That boy walking along with your daughter is my son, Harish. He is suffering from leukemia”. She paused to muffle her sobs. “Harish couldn’t attend the school last month. He lost all his

hair due to chemotherapy. He refused to come back to school fearing that his schoolmates might tease him. When Sindhu visited him last week, she promised she would take care of that teasing issue.

But, I never imagined she would sacrifice her lovely hair for the sake of my son! Sir, you and your wife are blessed to have such a noble soul as your daughter.

I stood transfixed, “My little Angel, you are teaching me how selfless real love is!” The happiest people on this planet are not those who live on their own terms but are those who change their terms for others and inspire others.

The Little Angel

LighterMoments

Ek yug tha jab log apne ghar ke dwar pe likhte the: Atithi Devo Bhava.

Phir likha: Shubh Laabh

Phir likhne lage: U R Welcome

Aur ab likhte hain: Kutton Se Savdhaan

Angry boss: Tumne kabhi Ullu dekha hai?

Executive (sar jhukate hue): Nahin sir.

Boss: Niche kya dekh rahe ho ? Meri taraf dekho.

Did you know?

It takes 8 minutes 17 seconds for light to travel from the Sun’s surface to

the Earth.

The earliest wine makers lived in Egypt around

2300 BC.

Female black widow spiders eat their males

after mating.

The tallest tree ever was an Australian

eucalyptus – In 1872 it was measured as

435 feet tall.

There are 60,000 miles

of blood vessels in the human body.

More germs are transferred

shaking hands than

kissing.

IpcaContact Editorial and Design Consultants: Yen Communication

MomentsLighter

Brain Twister #39 Winners

Chanchal K. ParetaJr. Officer – QC,

Pithampur

Aruna HemalCommercial, DGM

Mumbai

Rabindra Kumar Patra(Altus), Sr. RBMBhubaneshwar

Mala Devi SharmaSr. Depot Officer

Guwahati

S. K. Chatterjee(Altus), PSR

Kolkata

Santosh DeshmukhOfficer, R&DAurangabad

J. B. BhatnagarAsst. Manager

– Purchase, Indore

Santosh PariharCRD, Lab Assistant

Answer: 74658

Without using any reference material, can you find the hidden countries? In each case, the letter indicates the first letter of the country in question, the number represents the number of letters in the country. For example, E7 would be England.

Z6, L10, I9, E7, B6, J7, P8, M10, P4, F4

Rules: Contest restricted to employees of Ipca group of companies only. Last date for receiving entries is September 30, ‘08. Please send in your replies to Ms. Niveditha Rai, Mumbai, in detail.

Brain Twister #40

A man had forgotten his code to get into his work building...

of Ratlam Plant

An Aerial View

Editorial and Design Consultants: Yen Communication